|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions decreases expression increases expression |
ISO EXP |
[Cyclophosphamide results in increased activity of NR1I2 protein] which results in increased expression of ABCB1 mRNA; ABCB1 protein affects the susceptibility to [Cyclophosphamide co-treated with Methotrexate co-treated with Fluorouracil]; ABCB1 protein affects the susceptibility to [Fluorouracil co-treated with Epirubicin co-treated with Cyclophosphamide]; NR1I2 protein promotes the reaction [Cyclophosphamide results in increased expression of ABCB1 protein] Cyclophosphamide results in decreased expression of ABCB1 mRNA; Cyclophosphamide results in decreased expression of ABCB1A mRNA |
CTD |
PMID:12576456 PMID:20041327 PMID:20623750 PMID:30563925 |
|
NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
multiple interactions decreases response to substance |
ISO |
ABCC1 protein affects the susceptibility to [Fluorouracil co-treated with Epirubicin co-treated with Cyclophosphamide] ABCC1 protein results in decreased susceptibility to Cyclophosphamide |
CTD |
PMID:11778547 PMID:12576456 |
|
NCBI chr10:549,537...672,235
Ensembl chr10:549,883...672,196
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions |
ISO |
ABCG2 protein affects the susceptibility to [Fluorouracil co-treated with Epirubicin co-treated with Cyclophosphamide] |
CTD |
PMID:12576456 |
|
NCBI chr 4:88,765,441...88,890,268
Ensembl chr 4:88,832,178...88,890,621
|
|
G |
Abhd3 |
abhydrolase domain containing 3, phospholipase |
increases expression |
ISO |
Cyclophosphamide results in increased expression of ABHD3 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr18:1,892,413...1,946,840
Ensembl chr18:1,892,413...1,946,840
|
|
G |
Abi2 |
abl-interactor 2 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of ABI2 mRNA |
CTD |
PMID:27466211 |
|
NCBI chr 9:67,234,612...67,284,504
Ensembl chr 9:67,234,303...67,282,600
|
|
G |
Ace |
angiotensin I converting enzyme |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of ACE mRNA |
CTD |
PMID:27281708 |
|
NCBI chr10:94,170,766...94,213,831
Ensembl chr10:94,170,766...94,187,822
|
|
G |
Ace2 |
angiotensin I converting enzyme 2 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of ACE2 mRNA |
CTD |
PMID:32808185 |
|
NCBI chr X:32,050,734...32,095,860
Ensembl chr X:32,049,931...32,096,016
|
|
G |
Ackr3 |
atypical chemokine receptor 3 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of ACKR3 mRNA |
CTD |
PMID:20032115 |
|
NCBI chr 9:97,355,881...97,367,455
Ensembl chr 9:97,355,924...97,367,445
|
|
G |
Acod1 |
aconitate decarboxylase 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of ACOD1 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr15:93,612,968...93,622,322
Ensembl chr15:93,612,971...93,622,358
|
|
G |
Actb |
actin, beta |
decreases expression affects expression |
ISO EXP |
Cyclophosphamide results in decreased expression of ACTB mRNA Cyclophosphamide affects the expression of ACTB mRNA |
CTD |
PMID:10859244 PMID:12167460 |
|
NCBI chr12:13,715,843...13,718,813
Ensembl chr12:13,715,843...13,718,841
|
|
G |
Adam24 |
a disintegrin and metallopeptidase domain 24 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of ADAM24 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr16:54,625,789...54,631,824
Ensembl chr16:54,625,847...54,628,458
|
|
G |
Adamts9 |
ADAM metallopeptidase with thrombospondin type 1 motif, 9 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of ADAMTS9 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 4:124,660,254...124,860,997
Ensembl chr 4:124,660,262...124,858,250
|
|
G |
Adcyap1 |
adenylate cyclase activating polypeptide 1 |
affects expression increases expression |
EXP |
Cyclophosphamide affects the expression of ADCYAP1 mRNA Cyclophosphamide results in increased expression of ADCYAP1 protein |
CTD |
PMID:9776515 PMID:10754506 PMID:18563302 |
|
NCBI chr 9:121,705,897...121,725,736
Ensembl chr 9:121,706,979...121,725,716
|
|
G |
Adcyap1r1 |
ADCYAP receptor type I |
affects expression |
EXP |
Cyclophosphamide affects the expression of ADCYAP1R1 mRNA |
CTD |
PMID:18563302 |
|
NCBI chr 4:85,662,809...85,711,696
Ensembl chr 4:85,662,892...85,711,696
|
|
G |
Adm |
adrenomedullin |
affects response to substance |
ISO |
ADM protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr 1:175,443,189...175,447,260
Ensembl chr 1:175,445,088...175,447,259
|
|
G |
Afp |
alpha-fetoprotein |
affects expression |
ISO |
Cyclophosphamide affects the expression of AFP protein |
CTD |
PMID:6177358 |
|
NCBI chr14:19,141,755...19,159,919
Ensembl chr14:19,141,755...19,159,923
|
|
G |
Agl |
amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase |
affects response to substance |
ISO |
AGL protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr 2:219,788,234...219,843,189
Ensembl chr 2:219,788,234...219,842,986
|
|
G |
Akap2 |
A-kinase anchoring protein 2 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of PALM2AKAP2 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 5:74,874,245...74,985,789
Ensembl chr 5:74,874,306...74,982,401
|
|
G |
Akap8 |
A-kinase anchoring protein 8 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of AKAP8 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 7:14,323,298...14,339,953
Ensembl chr 7:14,324,104...14,351,918
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions decreases expression |
EXP |
Cyclophosphamide results in increased phosphorylation of and results in increased activity of AKT1 protein; NGF protein affects the reaction [Cyclophosphamide results in increased phosphorylation of and results in increased activity of AKT1 protein]; Plant Extracts inhibits the reaction [Cyclophosphamide results in decreased expression of AKT1 protein] |
CTD |
PMID:19996110 PMID:25446862 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Alad |
aminolevulinate dehydratase |
multiple interactions |
ISO |
[Cyclophosphamide co-treated with Carmustine co-treated with Etoposide] results in decreased activity of ALAD protein |
CTD |
PMID:19162187 |
|
NCBI chr 5:78,368,867...78,379,206
Ensembl chr 5:78,368,867...78,379,346
|
|
G |
Alcam |
activated leukocyte cell adhesion molecule |
increases expression |
ISO |
Cyclophosphamide results in increased expression of ALCAM mRNA |
CTD |
PMID:21041162 |
|
NCBI chr11:50,780,735...50,985,083
Ensembl chr11:50,781,127...50,985,083
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
affects response to substance increases expression decreases response to substance |
ISO |
ALDH1A1 protein affects the susceptibility to Cyclophosphamide Cyclophosphamide results in increased expression of ALDH1A1 mRNA ALDH1A1 protein results in decreased susceptibility to Cyclophosphamide |
CTD |
PMID:12513786 PMID:17403535 PMID:18854779 |
|
NCBI chr 1:238,222,689...238,264,381
Ensembl chr 1:238,222,521...238,264,330
|
|
G |
Aldh2 |
aldehyde dehydrogenase 2 family member |
increases expression |
ISO |
Cyclophosphamide results in increased expression of ALDH2 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr12:40,466,418...40,498,813
Ensembl chr12:40,466,495...40,498,752
|
|
G |
Aldh3a1 |
aldehyde dehydrogenase 3 family, member A1 |
affects response to substance |
ISO |
ALDH3A1 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:18854779 |
|
NCBI chr10:47,490,168...47,499,855
Ensembl chr10:47,490,153...47,499,876
|
|
G |
Alox5ap |
arachidonate 5-lipoxygenase activating protein |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of ALOX5AP mRNA |
CTD |
PMID:17403535 |
|
NCBI chr12:6,854,930...6,879,112
Ensembl chr12:6,854,920...6,879,154
|
|
G |
Alyref |
Aly/REF export factor |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of ALYREF mRNA |
CTD |
PMID:21041162 |
|
NCBI chr10:109,768,593...109,774,639
Ensembl chr10:109,770,876...109,774,639
|
|
G |
Amfr |
autocrine motility factor receptor |
multiple interactions |
ISO |
AMFR mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr19:11,473,538...11,509,500
Ensembl chr19:11,473,541...11,508,102
|
|
G |
Angpt1 |
angiopoietin 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of ANGPT1 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 7:81,338,327...81,592,459
Ensembl chr 7:81,342,280...81,592,206
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of APAF1 mRNA |
CTD |
PMID:29445054 |
|
NCBI chr 7:31,699,309...31,784,192
Ensembl chr 7:31,699,885...31,784,192
|
|
G |
Apex1 |
apurinic/apyrimidinic endodeoxyribonuclease 1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of APEX1 mRNA |
CTD |
PMID:11599041 |
|
NCBI chr15:27,849,943...27,852,083
Ensembl chr15:27,849,979...27,852,082
|
|
G |
Apob |
apolipoprotein B |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of APOB mRNA |
CTD |
PMID:18246545 |
|
NCBI chr 6:33,176,826...33,216,381
Ensembl chr 6:33,176,778...33,224,997
|
|
G |
Apoe |
apolipoprotein E |
decreases expression increases expression |
ISO |
Cyclophosphamide results in decreased expression of APOE mRNA Cyclophosphamide results in increased expression of APOE mRNA |
CTD |
PMID:15331540 PMID:21041162 |
|
NCBI chr 1:80,612,894...80,616,820
Ensembl chr 1:80,612,895...80,617,057
|
|
G |
Arg1 |
arginase 1 |
increases expression decreases expression affects expression |
ISO EXP |
Cyclophosphamide results in increased expression of ARG1 mRNA Cyclophosphamide results in decreased expression of ARG1 mRNA Cyclophosphamide affects the expression of ARG1 mRNA |
CTD |
PMID:18246545 PMID:21068404 |
|
NCBI chr 1:21,525,421...21,537,872
Ensembl chr 1:21,525,421...21,537,863
|
|
G |
Arhgdib |
Rho GDP dissociation inhibitor beta |
increases expression |
ISO |
Cyclophosphamide results in increased expression of ARHGDIB mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 4:170,913,920...170,932,789
Ensembl chr 4:170,913,923...170,932,618
|
|
G |
Arhgef26 |
Rho guanine nucleotide exchange factor 26 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of ARHGEF26 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr 2:27,107,263...27,236,336
Ensembl chr 2:27,107,318...27,236,672
|
|
G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of ASNS mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 4:33,742,876...33,761,106
Ensembl chr 4:33,743,364...33,761,163
|
|
G |
Atf2 |
activating transcription factor 2 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of ATF2 mRNA |
CTD |
PMID:11599041 |
|
NCBI chr 3:60,721,137...60,795,951
Ensembl chr 3:60,721,135...60,795,951
|
|
G |
Atf5 |
activating transcription factor 5 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of ATF5 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 1:100,807,821...100,812,410
Ensembl chr 1:100,808,241...100,810,522
|
|
G |
Atg3 |
autophagy related 3 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of ATG3 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr11:60,585,192...60,613,706
Ensembl chr11:60,585,171...60,613,718
|
|
G |
Atg5 |
autophagy related 5 |
decreases expression multiple interactions |
ISO |
Cyclophosphamide results in decreased expression of ATG5 protein Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of ATG5 protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of ATG5 protein] |
CTD |
PMID:32151603 |
|
NCBI chr20:49,301,783...49,393,147
Ensembl chr20:49,318,308...49,393,140
|
|
G |
Atg7 |
autophagy related 7 |
decreases expression multiple interactions |
ISO |
Cyclophosphamide results in decreased expression of ATG7 protein Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of ATG7 protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of ATG7 protein] |
CTD |
PMID:32151603 |
|
NCBI chr 4:146,570,113...146,777,093
Ensembl chr 4:146,598,413...146,777,124
|
|
G |
Aurkb |
aurora kinase B |
increases expression |
EXP |
Cyclophosphamide results in increased expression of AURKB mRNA |
CTD |
PMID:11599041 |
|
NCBI chr10:55,625,860...55,632,399
Ensembl chr10:55,626,741...55,634,991
|
|
G |
Axl |
Axl receptor tyrosine kinase |
increases expression |
ISO |
Cyclophosphamide results in increased expression of AXL mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 1:82,550,892...82,580,761
Ensembl chr 1:82,549,420...82,580,761
|
|
G |
B3galnt2 |
beta-1,3-N-acetylgalactosaminyltransferase 2 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of B3GALNT2 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr17:54,027,859...54,070,399
Ensembl chr17:54,027,859...54,070,399
|
|
G |
Bad |
BCL2-associated agonist of cell death |
increases expression multiple interactions |
EXP ISO |
Cyclophosphamide results in increased expression of BAD mRNA Cyclophosphamide results in increased expression of BAD protein Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in increased expression of BAD protein] |
CTD |
PMID:11599041 PMID:29753871 |
|
NCBI chr 1:222,198,516...222,207,459
Ensembl chr 1:222,198,534...222,207,453
|
|
G |
Bag1 |
BAG cochaperone 1 |
multiple interactions |
ISO |
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of BAG1 mRNA |
CTD |
PMID:16322899 |
|
NCBI chr 5:57,254,421...57,267,002
Ensembl chr 5:57,254,421...57,267,002
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions |
EXP ISO |
Cyclophosphamide results in increased expression of BAX mRNA; Cyclophosphamide results in increased expression of BAX protein Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in increased expression of BAX protein]; ganoderic acid A inhibits the reaction [Cyclophosphamide results in increased expression of BAX protein] Plant Extracts inhibits the reaction [Cyclophosphamide results in increased expression of BAX mRNA]; sacubitril-valsartan inhibits the reaction [Cyclophosphamide results in increased expression of BAX protein]; Valsartan inhibits the reaction [Cyclophosphamide results in increased expression of BAX protein] |
CTD |
PMID:25446862 PMID:29753871 PMID:30506662 PMID:32197949 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
increases expression multiple interactions |
EXP |
Cyclophosphamide results in increased expression of BBC3 mRNA sacubitril-valsartan inhibits the reaction [Cyclophosphamide results in increased expression of BBC3 mRNA]; Valsartan inhibits the reaction [Cyclophosphamide results in increased expression of BBC3 mRNA] |
CTD |
PMID:32197949 |
|
NCBI chr 1:78,261,491...78,267,802
|
|
G |
Bbs4 |
Bardet-Biedl syndrome 4 |
multiple interactions |
ISO |
BBS4 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr 8:64,115,005...64,154,432
Ensembl chr 8:64,121,392...64,154,396
|
|
G |
Bche |
butyrylcholinesterase |
multiple interactions decreases activity |
ISO |
[Melphalan co-treated with Thiotepa co-treated with Cyclophosphamide] results in decreased expression of BCHE protein Cyclophosphamide results in decreased activity of BCHE protein |
CTD |
PMID:4672170 PMID:4959505 |
|
NCBI chr 2:171,104,476...171,196,186
Ensembl chr 2:171,100,140...171,196,395
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression increases expression |
ISO EXP |
[Cladribine co-treated with Cyclophosphamide co-treated with Mitoxantrone] results in decreased expression of BCL2 protein; [Cladribine co-treated with Cyclophosphamide] results in decreased expression of BCL2 protein; [Doxorubicin co-treated with Cyclophosphamide] affects the expression of BCL2 mRNA; [Doxorubicin co-treated with Dexamethasone co-treated with Vincristine co-treated with Cytarabine co-treated with Mercaptopurine co-treated with Methotrexate co-treated with Cyclophosphamide co-treated with Enzymes and Coenzymes] results in increased expression of BCL2 protein; BCL2 protein inhibits the reaction [Cyclophosphamide results in increased activity of CASP3 protein]; BCL2 protein inhibits the reaction [Cyclophosphamide results in increased activity of CASP9 protein] Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of BCL2 protein]; ganoderic acid A inhibits the reaction [Cyclophosphamide results in decreased expression of BCL2 protein] Plant Extracts inhibits the reaction [Cyclophosphamide results in decreased expression of BCL2 mRNA]; sacubitril-valsartan inhibits the reaction [Cyclophosphamide results in decreased expression of BCL2 protein]; Valsartan inhibits the reaction [Cyclophosphamide results in decreased expression of BCL2 protein] Cyclophosphamide results in decreased expression of BCL2 mRNA; Cyclophosphamide results in decreased expression of BCL2 protein Cyclophosphamide results in increased expression of BCL2 mRNA |
CTD |
PMID:11723234 PMID:14503796 PMID:15582267 PMID:16322899 PMID:21182165 PMID:25446862 PMID:29753871 PMID:30506662 PMID:32197949 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of BCL2L1 mRNA |
CTD |
PMID:11599041 |
|
NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
|
|
G |
Bcl2l11 |
BCL2 like 11 |
increases expression multiple interactions |
EXP |
Cyclophosphamide results in increased expression of BCL2L11 mRNA sacubitril-valsartan inhibits the reaction [Cyclophosphamide results in increased expression of BCL2L11 mRNA]; Valsartan inhibits the reaction [Cyclophosphamide results in increased expression of BCL2L11 mRNA] |
CTD |
PMID:32197949 |
|
NCBI chr 3:120,726,906...120,764,192
Ensembl chr 3:120,726,906...120,764,192
|
|
G |
Bcl2l2 |
Bcl2-like 2 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of BCL2L2 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr15:33,543,774...33,549,165
Ensembl chr15:33,544,312...33,549,164
|
|
G |
Bcl6 |
BCL6, transcription repressor |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of BCL6 mRNA Cyclophosphamide metabolite results in decreased expression of BCL6 mRNA |
CTD |
PMID:21041162 PMID:24356939 |
|
NCBI chr11:80,255,790...80,279,075
Ensembl chr11:80,255,790...80,279,075
|
|
G |
Bdh1 |
3-hydroxybutyrate dehydrogenase 1 |
affects response to substance |
ISO |
BDH1 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr11:72,577,547...72,619,435
Ensembl chr11:72,578,533...72,614,176
|
|
G |
Bdkrb1 |
bradykinin receptor B1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of BDKRB1 mRNA |
CTD |
PMID:10498854 PMID:15576455 |
|
NCBI chr 6:129,437,423...129,441,553
Ensembl chr 6:129,438,158...129,440,574
|
|
G |
Bdkrb2 |
bradykinin receptor B2 |
affects expression |
EXP |
Cyclophosphamide affects the expression of BDKRB2 mRNA |
CTD |
PMID:15576455 |
|
NCBI chr 6:129,399,468...129,429,676
Ensembl chr 6:129,399,468...129,429,676
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
increases expression |
EXP |
Cyclophosphamide results in increased expression of BDNF mRNA |
CTD |
PMID:10683293 |
|
NCBI chr 3:100,768,637...100,819,216
Ensembl chr 3:100,768,637...100,819,210
|
|
G |
Becn1 |
beclin 1 |
multiple interactions decreases expression |
ISO |
BECN1 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of BECN1 protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of BECN1 protein] |
CTD |
PMID:16896004 PMID:32151603 |
|
NCBI chr10:89,209,944...89,225,297
Ensembl chr10:89,209,940...89,225,297
|
|
G |
Bik |
BCL2-interacting killer |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of BIK mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 7:124,390,924...124,410,449
Ensembl chr 7:124,391,432...124,410,447
|
|
G |
Birc3 |
baculoviral IAP repeat-containing 3 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of BIRC3 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 8:6,048,590...6,076,828
Ensembl chr 8:6,048,969...6,076,598
|
|
G |
Blvrb |
biliverdin reductase B |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of BLVRB protein |
CTD |
PMID:9006340 |
|
NCBI chr 1:84,256,063...84,273,726
Ensembl chr 1:84,256,159...84,274,075
|
|
G |
Bpi |
bactericidal/permeability-increasing protein |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of BPI mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 3:154,741,627...154,768,584
Ensembl chr 3:154,741,631...154,768,640
|
|
G |
Brpf1 |
bromodomain and PHD finger containing, 1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of BRPF1 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 4:145,264,445...145,280,943
Ensembl chr 4:145,264,462...145,280,857
|
|
G |
Bscl2 |
BSCL2 lipid droplet biogenesis associated, seipin |
increases expression |
ISO |
Cyclophosphamide results in increased expression of BSCL2 mRNA |
CTD |
PMID:22003191 |
|
NCBI chr 1:225,035,956...225,046,137
Ensembl chr 1:225,037,737...225,046,040
|
|
G |
Bsg |
basigin (Ok blood group) |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of BSG mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 7:12,875,536...12,882,753
Ensembl chr 7:12,875,537...12,882,753
|
|
G |
Btg1 |
BTG anti-proliferation factor 1 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of BTG1 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 7:37,812,831...37,815,088
Ensembl chr 7:37,812,831...37,815,088
|
|
G |
Btg2 |
BTG anti-proliferation factor 2 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of BTG2 mRNA |
CTD |
PMID:29445054 |
|
NCBI chr13:50,913,185...50,916,944
Ensembl chr13:50,913,180...50,916,982
|
|
G |
Btg3 |
BTG anti-proliferation factor 3 |
multiple interactions |
ISO |
BTG3 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr11:16,873,642...16,889,100
Ensembl chr11:16,873,646...16,889,201
|
|
G |
Bub3 |
BUB3 mitotic checkpoint protein |
multiple interactions |
ISO |
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of BUB3 mRNA |
CTD |
PMID:16322899 |
|
NCBI chr 1:203,526,853...203,537,459
Ensembl chr 1:203,524,426...203,557,337
|
|
G |
C1qa |
complement C1q A chain |
increases expression |
ISO |
Cyclophosphamide results in increased expression of C1QA mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 5:155,261,254...155,264,101
Ensembl chr 5:155,261,250...155,264,143
|
|
G |
C3 |
complement C3 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of C3 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 9:9,721,137...9,747,084
Ensembl chr 9:9,721,105...9,747,167
|
|
G |
Ca12 |
carbonic anhydrase 12 |
multiple interactions |
ISO |
CA12 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr 8:72,405,770...72,461,425
Ensembl chr 8:72,405,748...72,460,240
|
|
G |
Cabp1 |
calcium binding protein 1 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of CABP1 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr12:47,185,449...47,209,785
Ensembl chr12:47,179,664...47,209,784
|
|
G |
Cabp2 |
calcium binding protein 2 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of CABP2 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr 1:219,329,186...219,335,046
Ensembl chr 1:219,329,574...219,335,043
|
|
G |
Cacna1h |
calcium voltage-gated channel subunit alpha1 H |
increases expression multiple interactions |
ISO |
Cyclophosphamide results in increased expression of CACNA1H protein 3-cyanoalanine inhibits the reaction [[N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine co-treated with Cyclophosphamide] results in increased expression of CACNA1H protein]; [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine co-treated with Cyclophosphamide] results in increased expression of CACNA1H protein |
CTD |
PMID:29129814 |
|
NCBI chr10:14,730,932...14,789,201
Ensembl chr10:14,730,941...14,788,617
|
|
G |
Calr |
calreticulin |
increases expression decreases expression |
EXP |
Cyclophosphamide results in increased expression of CALR mRNA Cyclophosphamide results in decreased expression of CALR mRNA |
CTD |
PMID:11599041 PMID:11906922 PMID:18246545 |
|
NCBI chr19:25,956,771...25,961,666
Ensembl chr19:25,956,771...25,961,666
|
|
G |
Canx |
calnexin |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of CANX mRNA |
CTD |
PMID:11906922 |
|
NCBI chr10:35,800,942...35,833,939
Ensembl chr10:35,800,942...35,833,861
|
|
G |
Capn2 |
calpain 2 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CAPN2 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr13:100,878,649...100,928,811
Ensembl chr13:100,878,650...100,928,811
|
|
G |
Car2 |
carbonic anhydrase 2 |
decreases expression increases expression |
ISO |
Cyclophosphamide results in decreased expression of CA2 mRNA Cyclophosphamide results in increased expression of CAR2 mRNA |
CTD |
PMID:15331540 PMID:17403535 |
|
NCBI chr 2:88,097,740...88,112,868
Ensembl chr 2:88,097,720...88,113,029
|
|
G |
Car7 |
carbonic anhydrase 7 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of CAR7 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr19:636,545...645,935
Ensembl chr19:636,545...645,937
|
|
G |
Cars |
cysteinyl-tRNA synthetase |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of CARS1 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 1:216,759,367...216,801,652
Ensembl chr 1:216,759,366...216,801,656
|
|
G |
Casp1 |
caspase 1 |
decreases expression increases expression |
ISO |
Cyclophosphamide results in decreased expression of CASP1 mRNA Cyclophosphamide results in increased expression of CASP1 mRNA |
CTD |
PMID:17403535 PMID:21041162 |
|
NCBI chr 8:2,605,743...2,614,637
Ensembl chr 8:2,604,962...2,614,631
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity increases expression decreases response to substance |
ISO EXP |
[Bortezomib co-treated with oblimersen co-treated with Cyclophosphamide] results in increased activity of CASP3 protein; BCL2 protein inhibits the reaction [Cyclophosphamide results in increased activity of CASP3 protein]; Cyclophosphamide results in increased cleavage of and results in increased activity of CASP3 protein sacubitril-valsartan inhibits the reaction [Cyclophosphamide results in increased activity of CASP3 protein]; Valsartan inhibits the reaction [Cyclophosphamide results in increased activity of CASP3 protein] Cyclophosphamide results in increased expression of CASP3 protein ganoderic acid A inhibits the reaction [Cyclophosphamide results in increased expression of CASP3 protein] Cyclophosphamide results in increased expression of CASP3 mRNA CASP3 protein alternative form results in decreased susceptibility to Cyclophosphamide |
CTD |
PMID:11723234 PMID:14503796 PMID:16675587 PMID:17020986 PMID:17898787 PMID:30506662 PMID:32197949 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp4 |
caspase 4 |
increases cleavage multiple interactions |
EXP |
Cyclophosphamide results in increased cleavage of CASP4 protein sacubitril-valsartan inhibits the reaction [Cyclophosphamide results in increased cleavage of CASP4 protein]; Valsartan inhibits the reaction [Cyclophosphamide results in increased cleavage of CASP4 protein] |
CTD |
PMID:32197949 |
|
NCBI chr 8:2,616,391...2,651,682
Ensembl chr 8:2,635,851...2,651,652
|
|
G |
Casp8 |
caspase 8 |
multiple interactions increases response to substance |
ISO |
[Methotrexate results in increased expression of CASP8 protein] which results in increased susceptibility to Cyclophosphamide metabolite; Cyclophosphamide metabolite results in increased expression of and results in increased cleavage of CASP8 protein; Cyclophosphamide results in increased cleavage of and results in increased activity of CASP8 protein CASP8 protein results in increased susceptibility to Cyclophosphamide metabolite |
CTD |
PMID:17898787 PMID:22010212 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases expression increases activity |
ISO EXP |
BCL2 protein inhibits the reaction [Cyclophosphamide results in increased activity of CASP9 protein]; Cyclophosphamide results in increased cleavage of and results in increased activity of CASP9 protein ganoderic acid A inhibits the reaction [Cyclophosphamide results in increased expression of CASP9 protein] |
CTD |
PMID:11723234 PMID:17898787 PMID:30506662 |
|
NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
|
|
G |
Cat |
catalase |
decreases expression decreases activity affects activity multiple interactions |
EXP ISO |
Cyclophosphamide results in decreased expression of CAT protein Cyclophosphamide results in decreased activity of CAT protein Cyclophosphamide results in decreased expression of CAT mRNA; Cyclophosphamide results in decreased expression of CAT protein Cyclophosphamide affects the activity of CAT protein Buthionine Sulfoximine promotes the reaction [Cyclophosphamide results in decreased activity of CAT protein]; cinnamic acid inhibits the reaction [Cyclophosphamide affects the activity of CAT protein]; Cyclophosphamide promotes the reaction [NFE2L2 gene mutant form results in decreased expression of CAT protein]; Eicosapentaenoic Acid inhibits the reaction [Cyclophosphamide affects the activity of CAT protein]; Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased activity of CAT protein]; NFE2L2 gene mutant form promotes the reaction [Cyclophosphamide results in decreased expression of CAT protein]; Plant Extracts inhibits the reaction [Buthionine Sulfoximine promotes the reaction [Cyclophosphamide results in decreased activity of CAT protein]]; Plant Extracts inhibits the reaction [Cyclophosphamide results in decreased activity of CAT protein]; Plant Extracts inhibits the reaction [Cyclophosphamide results in decreased expression of CAT mRNA] mangiferin inhibits the reaction [Cyclophosphamide results in decreased activity of CAT protein]; Pentoxifylline inhibits the reaction [Cyclophosphamide results in decreased activity of CAT protein]; pimagedine inhibits the reaction [Cyclophosphamide results in decreased expression of CAT protein]; Rutin inhibits the reaction [Cyclophosphamide results in decreased activity of CAT protein]; thymoquinone inhibits the reaction [Cyclophosphamide results in decreased activity of CAT protein] |
CTD |
PMID:16076520 PMID:19107871 PMID:20052769 PMID:20957680 PMID:21772021 PMID:22285266 PMID:23542512 PMID:23695977 PMID:25753322 PMID:27633142 PMID:29753871 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Ccin |
calicin |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CCIN protein |
CTD |
PMID:17475930 |
|
NCBI chr 5:59,452,348...59,454,235
Ensembl chr 5:59,452,348...59,454,233
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
decreases expression increases expression |
EXP ISO |
Cyclophosphamide results in decreased expression of CCL2 protein Cyclophosphamide results in increased expression of CCL2 mRNA |
CTD |
PMID:18848347 PMID:21068404 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Ccl25 |
C-C motif chemokine ligand 25 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CCL25 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr12:2,429,492...2,438,928
Ensembl chr12:2,429,509...2,438,817
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CCL3 protein |
CTD |
PMID:21880982 |
|
NCBI chr10:70,869,516...70,871,066
Ensembl chr10:70,869,513...70,871,066
|
|
G |
Ccl7 |
C-C motif chemokine ligand 7 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CCL7 mRNA |
CTD |
PMID:15331540 PMID:21041162 |
|
NCBI chr10:69,423,083...69,424,933
Ensembl chr10:69,423,086...69,424,979
|
|
G |
Ccna2 |
cyclin A2 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CCNA2 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 2:123,274,727...123,282,266
Ensembl chr 2:123,275,881...123,282,214
|
|
G |
Ccnd2 |
cyclin D2 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CCND2 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 4:159,674,885...159,697,207
Ensembl chr 4:159,674,885...159,697,207
|
|
G |
Ccnd3 |
cyclin D3 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CCND3 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 9:15,404,816...15,410,905
Ensembl chr 9:15,404,822...15,410,943
|
|
G |
Ccr5 |
C-C motif chemokine receptor 5 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CCR5 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 8:133,192,398...133,215,599
Ensembl chr 8:133,197,032...133,215,614
|
|
G |
Ccr8 |
C-C motif chemokine receptor 8 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CCR8 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 8:128,779,552...128,782,531
Ensembl chr 8:128,781,395...128,782,456
|
|
G |
Ccr9 |
C-C motif chemokine receptor 9 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CCR9 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 8:132,827,325...132,842,130
Ensembl chr 8:132,828,091...132,842,130
|
|
G |
Cct3 |
chaperonin containing TCP1 subunit 3 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of CCT3 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr 2:187,669,051...187,693,610
Ensembl chr 2:187,668,796...187,693,610
|
|
G |
Cct5 |
chaperonin containing TCP1 subunit 5 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of CCT5 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr 2:84,667,578...84,678,730
Ensembl chr 2:84,667,633...84,678,790
|
|
G |
Cct7 |
chaperonin containing TCP1 subunit 7 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of CCT7 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr 4:117,235,023...117,252,265
Ensembl chr 4:117,235,023...117,252,265
|
|
G |
Cd14 |
CD14 molecule |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CD14 mRNA |
CTD |
PMID:15331540 PMID:21041162 |
|
NCBI chr18:29,560,341...29,562,290
Ensembl chr18:29,560,365...29,562,153
|
|
G |
Cd151 |
CD151 molecule (Raph blood group) |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CD151 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 1:214,446,659...214,450,668
Ensembl chr 1:214,009,784...214,013,765 Ensembl chr 1:214,009,784...214,013,765
|
|
G |
Cd2 |
Cd2 molecule |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CD2 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 2:203,666,706...203,680,073
Ensembl chr 2:203,666,637...203,680,083
|
|
G |
Cd27 |
CD27 molecule |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CD27 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 4:157,744,881...157,751,609
Ensembl chr 4:157,744,882...157,750,088
|
|
G |
Cd28 |
Cd28 molecule |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CD28 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 9:67,546,408...67,573,858
Ensembl chr 9:67,546,408...67,571,871
|
|
G |
Cd38 |
CD38 molecule |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CD38 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr14:71,714,768...71,754,990
Ensembl chr14:71,715,269...71,754,672
|
|
G |
Cd3d |
CD3d molecule |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CD3D mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 8:49,282,502...49,287,095
Ensembl chr 8:49,282,460...49,287,110
|
|
G |
Cd3e |
CD3e molecule |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CD3E mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 8:49,297,604...49,309,370
Ensembl chr 8:49,297,608...49,308,806
|
|
G |
Cd3g |
CD3g molecule |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CD3G mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 8:49,274,553...49,280,943
Ensembl chr 8:49,274,960...49,280,901
|
|
G |
Cd4 |
Cd4 molecule |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CD4 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 4:157,381,862...157,408,357
Ensembl chr 4:157,383,052...157,408,176
|
|
G |
Cd40 |
CD40 molecule |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CD40 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 3:161,519,789...161,534,943
Ensembl chr 3:161,519,743...161,534,704
|
|
G |
Cd5 |
Cd5 molecule |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CD5 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 1:226,770,912...226,791,861
Ensembl chr 1:226,770,744...226,791,879
|
|
G |
Cd6 |
Cd6 molecule |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CD6 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 1:226,848,399...226,887,259
Ensembl chr 1:226,848,403...226,887,156
|
|
G |
Cd69 |
Cd69 molecule |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CD69 mRNA Cyclophosphamide metabolite results in decreased expression of CD69 mRNA |
CTD |
PMID:21041162 PMID:24356939 |
|
NCBI chr 4:163,041,147...163,049,065
Ensembl chr 4:163,041,141...163,049,084
|
|
G |
Cd74 |
CD74 molecule |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CD74 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr18:56,071,420...56,080,851
Ensembl chr18:56,071,478...56,080,849
|
|
G |
Cd79b |
CD79b molecule |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CD79B mRNA |
CTD |
PMID:15331540 |
|
NCBI chr10:94,497,445...94,500,591
Ensembl chr10:94,497,448...94,500,591
|
|
G |
Cd83 |
CD83 molecule |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CD83 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr17:24,416,651...24,435,790
Ensembl chr17:24,416,651...24,435,790
|
|
G |
Cd84 |
CD84 molecule |
increases expression |
ISO |
Cyclophosphamide metabolite results in increased expression of CD84 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr13:90,241,369...90,283,625
Ensembl chr13:90,244,681...90,277,865
|
|
G |
Cd8a |
CD8a molecule |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CD8A mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 4:99,217,640...99,243,352
Ensembl chr 4:99,239,115...99,243,351
|
|
G |
Cd8b |
CD8b molecule |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CD8B1 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 4:99,185,960...99,201,887
Ensembl chr 4:99,185,885...99,202,023
|
|
G |
Cdc20 |
cell division cycle 20 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of CDC20 mRNA |
CTD |
PMID:11599041 |
|
NCBI chr 5:137,260,728...137,264,931
Ensembl chr 5:137,260,739...137,265,015
|
|
G |
Cdh1 |
cadherin 1 |
affects expression |
EXP |
Cyclophosphamide affects the expression of CDH1 mRNA |
CTD |
PMID:10859244 |
|
NCBI chr19:38,768,467...38,838,395
Ensembl chr19:38,768,467...38,838,395
|
|
G |
Cdh2 |
cadherin 2 |
affects expression |
EXP |
Cyclophosphamide affects the expression of CDH2 mRNA |
CTD |
PMID:10859244 |
|
NCBI chr18:8,146,971...8,366,037
Ensembl chr18:8,146,971...8,360,684
|
|
G |
Cdh3 |
cadherin 3 |
affects expression |
EXP |
Cyclophosphamide affects the expression of CDH3 mRNA |
CTD |
PMID:10859244 |
|
NCBI chr19:38,668,957...38,719,801
Ensembl chr19:38,669,230...38,719,677
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CDK2 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 7:3,124,953...3,132,533
Ensembl chr 7:3,124,954...3,132,457
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CDKN1A mRNA |
CTD |
PMID:15331540 PMID:21527772 PMID:29445054 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
multiple interactions |
ISO |
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of CDKN1B mRNA |
CTD |
PMID:16322899 |
|
NCBI chr 4:168,689,043...168,694,159
Ensembl chr 4:168,689,163...168,693,964
|
|
G |
Cdkn1c |
cyclin-dependent kinase inhibitor 1C |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CDKN1C mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 1:216,661,067...216,663,791
Ensembl chr 1:216,661,080...216,663,721
|
|
G |
Cdkn2d |
cyclin dependent kinase inhibitor 2D |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CDKN2D mRNA |
CTD |
PMID:21041162 |
|
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of CEBPB mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 3:164,424,502...164,425,933
Ensembl chr 3:164,424,515...164,425,910
|
|
G |
Cel |
carboxyl ester lipase |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CEL mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 3:7,134,021...7,141,522
Ensembl chr 3:7,134,021...7,141,522
|
|
G |
Cfb |
complement factor B |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CFB mRNA |
CTD |
PMID:21041162 |
|
NCBI chr20:4,536,206...4,542,073
Ensembl chr20:4,536,203...4,561,066 Ensembl chr20:4,536,203...4,561,066
|
|
G |
Cfi |
complement factor I |
affects response to substance |
ISO |
CFI protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr 2:235,264,149...235,305,779
Ensembl chr 2:235,264,219...235,305,781
|
|
G |
Chac1 |
ChaC glutathione-specific gamma-glutamylcyclotransferase 1 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of CHAC1 mRNA; Cyclophosphamide results in decreased expression of CHAC1 mRNA |
CTD |
PMID:23824090 PMID:24356939 |
|
NCBI chr 3:111,160,205...111,163,425
Ensembl chr 3:111,160,205...111,163,425
|
|
G |
Champ1 |
chromosome alignment maintaining phosphoprotein 1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of CHAMP1 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr16:80,839,373...80,850,340
Ensembl chr16:80,839,374...80,850,340
|
|
G |
Chd5 |
chromodomain helicase DNA binding protein 5 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of CHD5 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 5:169,519,212...169,572,059
Ensembl chr 5:169,519,212...169,567,107
|
|
G |
Chga |
chromogranin A |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CHGA mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 6:126,434,226...126,445,569
Ensembl chr 6:126,434,226...126,445,568
|
|
G |
Chrm5 |
cholinergic receptor, muscarinic 5 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of CHRM5 protein |
CTD |
PMID:16125470 |
|
NCBI chr 3:103,966,451...104,018,815
Ensembl chr 3:103,966,451...104,018,861
|
|
G |
Cited2 |
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 |
affects expression decreases expression |
EXP |
Cyclophosphamide affects the expression of CITED2 mRNA Cyclophosphamide results in decreased expression of CITED2 mRNA |
CTD |
PMID:18246545 |
|
NCBI chr 1:12,823,363...12,825,806
Ensembl chr 1:12,823,363...12,825,786
|
|
G |
Cldn1 |
claudin 1 |
multiple interactions decreases expression |
ISO |
Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of CLDN1 protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of CLDN1 protein] |
CTD |
PMID:32151603 |
|
NCBI chr11:77,815,216...77,830,373
Ensembl chr11:77,815,181...77,830,416
|
|
G |
Cldn4 |
claudin 4 |
multiple interactions decreases expression |
EXP |
Anthocyanins inhibits the reaction [Cyclophosphamide results in decreased expression of CLDN4 protein]; Plant Extracts inhibits the reaction [Cyclophosphamide results in decreased expression of CLDN4 protein] |
CTD |
PMID:25451569 |
|
NCBI chr12:24,761,210...24,763,008
Ensembl chr12:24,761,210...24,763,005
|
|
G |
Clic4 |
chloride intracellular channel 4 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CLIC4 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 5:153,568,937...153,625,669
Ensembl chr 5:153,568,745...153,625,869
|
|
G |
Clip1 |
CAP-GLY domain containing linker protein 1 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of CLIP1 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr12:38,345,203...38,452,650
Ensembl chr12:38,345,456...38,452,652
|
|
G |
Coch |
cochlin |
affects response to substance |
ISO |
COCH protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr 6:72,359,702...72,373,710
Ensembl chr 6:72,359,791...72,373,695
|
|
G |
Comt |
catechol-O-methyltransferase |
increases expression |
ISO |
Cyclophosphamide results in increased expression of COMT mRNA |
CTD |
PMID:21041162 |
|
NCBI chr11:86,715,981...86,735,630
Ensembl chr11:86,715,981...86,735,622
|
|
G |
Cox7a2 |
cytochrome c oxidase subunit 7A2 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of COX7A2 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 8:87,209,529...87,213,627
Ensembl chr 8:87,209,530...87,213,627
|
|
G |
Crabp2 |
cellular retinoic acid binding protein 2 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CRABP2 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 2:187,322,416...187,326,794
Ensembl chr 2:184,882,969...184,883,505
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CREB1 protein modified form |
CTD |
PMID:18299998 |
|
NCBI chr 9:71,229,753...71,298,994
Ensembl chr 9:71,230,108...71,293,435
|
|
G |
Crem |
cAMP responsive element modulator |
decreases expression multiple interactions |
EXP |
Cyclophosphamide results in decreased expression of CREM mRNA; Cyclophosphamide results in decreased expression of CREM protein Drugs, Chinese Herbal inhibits the reaction [Cyclophosphamide results in decreased expression of CREM mRNA]; Drugs, Chinese Herbal inhibits the reaction [Cyclophosphamide results in decreased expression of CREM protein] |
CTD |
PMID:17624719 |
|
NCBI chr17:57,021,704...57,090,888
Ensembl chr17:57,031,766...57,090,888
|
|
G |
Crh |
corticotropin releasing hormone |
increases expression |
EXP ISO |
Cyclophosphamide results in increased expression of CRH mRNA; Cyclophosphamide results in increased expression of CRH protein |
CTD |
PMID:15276878 PMID:16614059 PMID:17335920 |
|
NCBI chr 2:104,459,999...104,461,863
Ensembl chr 2:104,459,999...104,461,863
|
|
G |
Crhr2 |
corticotropin releasing hormone receptor 2 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of CRHR2 protein |
CTD |
PMID:16614059 |
|
NCBI chr 4:85,286,371...85,329,374
Ensembl chr 4:85,286,372...85,329,362
|
|
G |
Csf1 |
colony stimulating factor 1 |
multiple interactions |
ISO |
[Cyclophosphamide co-treated with Sizofiran] results in increased expression of CSF1 mRNA |
CTD |
PMID:10052129 |
|
NCBI chr 2:210,522,370...210,550,546
Ensembl chr 2:210,522,375...210,550,560
|
|
G |
Csf2 |
colony stimulating factor 2 |
affects activity increases expression |
ISO EXP |
CSF2 protein affects the activity of Cyclophosphamide Cyclophosphamide results in increased expression of CSF2 protein |
CTD |
PMID:8349185 PMID:18848347 |
|
NCBI chr10:39,602,089...39,604,070
Ensembl chr10:39,602,089...39,604,070
|
|
G |
Csk |
C-terminal Src kinase |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CSK mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 8:62,405,714...62,424,707
Ensembl chr 8:62,405,715...62,424,303
|
|
G |
Cst7 |
cystatin F |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CST7 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 3:146,363,913...146,373,365
Ensembl chr 3:146,365,092...146,373,365
|
|
G |
Csta |
cystatin A |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of CSTA mRNA |
CTD |
PMID:24356939 |
|
NCBI chr11:67,555,792...67,566,980
Ensembl chr11:67,555,658...67,566,972
|
|
G |
Cth |
cystathionine gamma-lyase |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CTH protein |
CTD |
PMID:29129814 |
|
NCBI chr 2:264,266,959...264,293,040
Ensembl chr 2:264,266,984...264,293,046
|
|
G |
Ctnnbip1 |
catenin, beta-interacting protein 1 |
multiple interactions |
ISO |
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of CTNNBIP1 mRNA |
CTD |
PMID:16322899 |
|
NCBI chr 5:166,464,170...166,513,030
Ensembl chr 5:166,464,252...166,513,027
|
|
G |
Ctnnd2 |
catenin delta 2 |
multiple interactions |
ISO |
CTNND2 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr 2:83,227,247...84,094,315
Ensembl chr 2:83,393,282...84,094,315
|
|
G |
Ctsd |
cathepsin D |
multiple interactions increases activity |
ISO EXP |
[Cyclophosphamide co-treated with Mecamylamine] results in increased expression of CTSD mRNA Cyclophosphamide results in increased activity of CTSD protein Anthocyanins inhibits the reaction [Cyclophosphamide results in increased activity of CTSD protein]; Plant Extracts inhibits the reaction [Cyclophosphamide results in increased activity of CTSD protein] |
CTD |
PMID:18433785 PMID:25451569 |
|
NCBI chr 1:215,541,570...215,553,446
Ensembl chr 1:215,541,542...215,553,451
|
|
G |
Ctsh |
cathepsin H |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CTSH mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 8:97,439,155...97,458,293
Ensembl chr 8:97,439,161...97,458,287
|
|
G |
Ctsl |
cathepsin L |
increases expression decreases expression multiple interactions |
ISO |
Cyclophosphamide results in increased expression of CTSL mRNA Cyclophosphamide results in decreased expression of CTSL mRNA 5-(N-methyl-N-propargylaminomethyl)-8-hydroxyquinoline inhibits the reaction [Cyclophosphamide results in decreased expression of CTSL mRNA] |
CTD |
PMID:17403535 PMID:30760223 |
|
NCBI chr17:1,873,105...1,879,266
Ensembl chr17:1,872,848...1,879,279
|
|
G |
Cx3cl1 |
C-X3-C motif chemokine ligand 1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of CX3CL1 protein |
CTD |
PMID:16651033 |
|
NCBI chr19:10,644,267...10,654,861
Ensembl chr19:10,644,244...10,653,800
|
|
G |
Cx3cr1 |
C-X3-C motif chemokine receptor 1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of CX3CR1 protein |
CTD |
PMID:16651033 |
|
NCBI chr 8:128,740,756...128,754,514
Ensembl chr 8:128,740,756...128,754,514
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of CXCL1 protein |
CTD |
PMID:18848347 |
|
NCBI chr14:18,743,678...18,745,457
Ensembl chr14:18,743,685...18,745,457
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
affects expression increases expression increases response to substance |
ISO |
Cyclophosphamide affects the expression of CXCL10 mRNA Cyclophosphamide results in increased expression of CXCL10 protein CXCL10 protein results in increased susceptibility to Cyclophosphamide |
CTD |
PMID:18957084 |
|
NCBI chr14:17,210,733...17,212,930
Ensembl chr14:17,210,733...17,212,930
|
|
G |
Cxcl11 |
C-X-C motif chemokine ligand 11 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CXCL11 protein |
CTD |
PMID:18957084 |
|
NCBI chr14:17,195,395...17,198,170
Ensembl chr14:17,195,014...17,198,291
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
affects expression increases expression |
ISO EXP |
Cyclophosphamide affects the expression of CXCL12 mRNA Cyclophosphamide results in increased expression of CXCL12 mRNA; Cyclophosphamide results in increased expression of CXCL12 protein |
CTD |
PMID:12624490 PMID:16337237 PMID:19066630 PMID:20032115 |
|
NCBI chr 4:149,261,044...149,273,891
Ensembl chr 4:149,261,044...149,273,891
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
increases expression affects expression multiple interactions |
ISO |
Cyclophosphamide results in increased expression of CXCL1 mRNA; Cyclophosphamide results in increased expression of CXCL1 protein Cyclophosphamide affects the expression of CXCL3 mRNA VIP protein inhibits the reaction [Cyclophosphamide results in increased expression of CXCL1 protein] |
CTD |
PMID:15331540 PMID:18483878 PMID:18957084 |
|
NCBI chr14:18,820,168...18,839,659
Ensembl chr14:18,820,168...18,839,595
|
|
G |
Cxcl9 |
C-X-C motif chemokine ligand 9 |
affects expression decreases expression increases expression |
ISO |
Cyclophosphamide affects the expression of CXCL9 mRNA Cyclophosphamide results in decreased expression of CXCL9 protein Cyclophosphamide results in increased expression of CXCL9 mRNA; Cyclophosphamide results in increased expression of CXCL9 protein |
CTD |
PMID:15331540 PMID:18957084 PMID:21041162 PMID:21880982 |
|
NCBI chr14:17,228,832...17,233,743
Ensembl chr14:17,228,856...17,234,712
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
multiple interactions decreases expression increases expression affects localization |
EXP ISO |
Cyclophosphamide promotes the reaction [MIF protein binds to CXCR4 protein] Cyclophosphamide results in decreased expression of CXCR4 mRNA Cyclophosphamide results in increased expression of CXCR4 mRNA; Cyclophosphamide results in increased expression of CXCR4 protein Cyclophosphamide affects the localization of CXCR4 protein |
CTD |
PMID:19066630 PMID:20032115 PMID:21041162 |
|
NCBI chr13:45,314,952...45,318,856
Ensembl chr13:45,314,933...45,318,878
|
|
G |
Cxcr6 |
C-X-C motif chemokine receptor 6 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of CXCR6 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 8:132,869,712...132,870,766
Ensembl chr 8:132,869,712...132,870,767
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases activity |
ISO |
Cyclophosphamide results in decreased activity of CYP1A1 protein |
CTD |
PMID:18420780 |
|
NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
decreases activity |
ISO |
Cyclophosphamide results in decreased activity of CYP1A2 protein |
CTD |
PMID:18420780 |
|
NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of CYP1B1 mRNA |
CTD |
PMID:12167460 |
|
NCBI chr 6:2,308,179...2,316,739
Ensembl chr 6:2,307,808...2,316,722
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
multiple interactions increases expression increases response to substance affects metabolic processing increases activity increases hydroxylation increases metabolic processing |
EXP ISO |
Cyclophosphamide results in increased expression of and results in increased activity of CYP2B1 protein; Metyrapone inhibits the reaction [CYP2B1 results in increased susceptibility to Cyclophosphamide] Cyclophosphamide results in increased expression of CYP2B10 mRNA CYP2B1 protein results in increased susceptibility to Cyclophosphamide; CYP2B1 results in increased susceptibility to Cyclophosphamide CYP2B1 protein affects the metabolism of Cyclophosphamide CYP2B1 results in increased activity of Cyclophosphamide CYP2B1 protein mutant form results in increased hydroxylation of Cyclophosphamide; CYP2B1 protein results in increased hydroxylation of Cyclophosphamide Cyclophosphamide results in increased expression of CYP2B1 mRNA; Cyclophosphamide results in increased expression of CYP2B1 protein CYP2B1 protein results in increased metabolism of Cyclophosphamide; CYP2B1 results in increased metabolism of Cyclophosphamide |
CTD |
PMID:2272335 PMID:7834628 PMID:8640822 PMID:9592392 PMID:10415877 PMID:11221871 PMID:11933215 PMID:15102956 PMID:15635577 PMID:16019949 PMID:17634551 PMID:19103281 PMID:20566340 PMID:24819615 |
|
NCBI chr 7:99,142,431...99,183,540
Ensembl chr 7:99,142,450...99,181,783
|
|
G |
Cyp2b2 |
cytochrome P450, family 2, subfamily b, polypeptide 2 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of CYP2B2 mRNA; Cyclophosphamide results in increased expression of CYP2B2 protein |
CTD |
PMID:16019949 PMID:17634551 |
|
NCBI chr 1:83,103,925...83,119,578
Ensembl chr 1:83,103,925...83,119,193
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
multiple interactions increases metabolic processing increases activity increases response to substance increases hydroxylation affects hydroxylation |
ISO EXP |
[Cyclophosphamide results in increased activity of NR1I3 protein alternative form] which results in increased expression of CYP2B6 mRNA; [Doxorubicin co-treated with Cyclophosphamide] affects the expression of CYP2B6 mRNA; Cyclophosphamide results in decreased expression of and results in decreased activity of CYP2B6 protein; CYP2B6 protein polymorphism affects the activity of and affects the susceptibility to Cyclophosphamide; CYP2B6 protein results in increased metabolism of and results in increased susceptibility to Cyclophosphamide; POR promotes the reaction [CYP2B6 results in increased susceptibility to Cyclophosphamide]; POR protein promotes the reaction [CYP2B6 protein results in increased susceptibility to Cyclophosphamide] CYP2B6 protein results in increased metabolism of Cyclophosphamide CYP2B6 protein results in increased activity of Cyclophosphamide CYP2B6 protein results in increased susceptibility to Cyclophosphamide; CYP2B6 results in increased susceptibility to Cyclophosphamide CYP2B6 protein results in increased hydroxylation of Cyclophosphamide CYP2B6 intron polymorphism affects the hydroxylation of Cyclophosphamide; CYP2B6 promoter polymorphism affects the hydroxylation of Cyclophosphamide |
CTD |
PMID:9766669 PMID:10919648 PMID:11389073 PMID:11723234 PMID:12498089 PMID:12872138 PMID:15248218 PMID:15769884 PMID:16183265 PMID:16322899 PMID:17041008 PMID:17502835 PMID:18212249 PMID:18633247 PMID:24819615 PMID:25860621 |
|
NCBI chr 1:83,163,103...83,236,615
Ensembl chr 1:83,163,079...83,236,615
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
increases expression increases metabolic processing |
EXP |
Cyclophosphamide results in increased expression of CYP2C11 mRNA CYP2C11 results in increased metabolism of Cyclophosphamide |
CTD |
PMID:16019949 PMID:20566340 |
|
NCBI chr 1:257,676,172...258,004,428
Ensembl chr 1:257,970,345...258,004,434
|
|
G |
Cyp2c24 |
cytochrome P450, family 2, subfamily c, polypeptide 24 |
multiple interactions increases response to substance increases activity |
ISO |
POR promotes the reaction [CYP2C18 results in increased susceptibility to Cyclophosphamide] CYP2C18 results in increased activity of Cyclophosphamide |
CTD |
PMID:9241661 PMID:9766669 |
|
NCBI chr 1:258,074,797...258,139,176
Ensembl chr 1:258,074,860...258,139,176
|
|
G |
Cyp2c6v1 |
cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 |
increases metabolic processing increases response to substance increases hydroxylation increases activity multiple interactions decreases metabolic processing |
EXP ISO |
CYP2C6V1 results in increased metabolism of Cyclophosphamide CYP2C19 protein results in increased susceptibility to Cyclophosphamide CYP2C19 protein results in increased hydroxylation of Cyclophosphamide CYP2C19 results in increased activity of Cyclophosphamide CYP2C19 protein results in increased metabolism of Cyclophosphamide [CYP2C19 protein results in increased hydroxylation of Cyclophosphamide] which results in increased chemical synthesis of 4-hydroxycyclophosphamide; [CYP2C19 protein results in increased hydroxylation of Cyclophosphamide] which results in increased chemical synthesis of Acrolein; CYP2C19 protein polymorphism affects the activity of and affects the susceptibility to Cyclophosphamide CYP2C19 gene polymorphism results in decreased metabolism of Cyclophosphamide |
CTD |
PMID:9241661 PMID:15248218 PMID:16116487 PMID:20566340 PMID:30500380 |
|
NCBI chr 1:147,713,879...147,814,410
Ensembl chr 1:147,713,892...147,888,007
|
|
G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
increases activity increases expression |
ISO |
CYP2C8 results in increased activity of Cyclophosphamide Cyclophosphamide results in increased expression of CYP2C29 mRNA |
CTD |
PMID:9241661 PMID:24819615 |
|
NCBI chr 1:147,236,480...147,307,988
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
increases metabolic processing |
ISO |
CYP2D6 protein results in increased metabolism of Cyclophosphamide |
CTD |
PMID:11377097 |
|
NCBI chr 7:123,599,264...123,608,436
Ensembl chr 7:123,599,266...123,608,436
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
increases metabolic processing |
EXP |
CYP2E1 results in increased metabolism of Cyclophosphamide |
CTD |
PMID:20566340 |
|
NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of CYP3A2 mRNA; Cyclophosphamide results in increased expression of CYP3A2 protein |
CTD |
PMID:16019949 |
|
NCBI chr12:11,641,500...11,677,818
Ensembl chr12:11,655,402...11,733,136
|
|
G |
Cyp3a23-3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 |
affects expression decreases expression |
EXP |
Cyclophosphamide affects the expression of CYP3A23-3A1 mRNA Cyclophosphamide results in decreased expression of CYP3A23-3A1 mRNA |
CTD |
PMID:18246545 |
|
NCBI chr12:11,053,888...11,082,742
Ensembl chr12:11,655,402...11,733,136
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
increases metabolic processing affects response to substance increases expression affects metabolic processing increases response to substance multiple interactions increases hydroxylation |
ISO |
CYP3A4 protein results in increased metabolism of Cyclophosphamide CYP3A4 gene polymorphism affects the susceptibility to Cyclophosphamide Cyclophosphamide results in increased expression of CYP3A4 mRNA CYP3A4 protein affects the metabolism of Cyclophosphamide CYP3A4 protein results in increased susceptibility to Cyclophosphamide [Cyclophosphamide results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; [CYP3A4 protein results in increased hydroxylation of Cyclophosphamide] which results in increased chemical synthesis of 4-hydroxycyclophosphamide; [CYP3A4 protein results in increased hydroxylation of Cyclophosphamide] which results in increased chemical synthesis of Acrolein; CYP3A4 gene affects the susceptibility to [Carmustine co-treated with Cyclophosphamide co-treated with Cisplatin]; CYP3A4 protein results in increased metabolism of and results in increased susceptibility to Cyclophosphamide |
CTD |
PMID:11377097 PMID:16087946 PMID:17041008 PMID:18839173 PMID:25860621 PMID:26718876 PMID:30500380 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
affects metabolic processing increases expression multiple interactions affects response to substance |
ISO |
CYP3A5 protein affects the metabolism of Cyclophosphamide Cyclophosphamide results in increased expression of CYP3A13 mRNA CYP3A5 gene affects the susceptibility to [Carmustine co-treated with Cyclophosphamide co-treated with Cisplatin] CYP3A5 gene polymorphism affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16087946 PMID:24819615 |
|
NCBI chr12:19,074,288...19,114,491
Ensembl chr12:19,074,583...19,114,399
|
|
G |
Dcn |
decorin |
multiple interactions |
ISO |
DCN protein inhibits the reaction [TGFB1 protein results in decreased susceptibility to [Cyclophosphamide co-treated with Cisplatin co-treated with Melphalan co-treated with Thiotepa]] |
CTD |
PMID:9509296 |
|
NCBI chr 7:38,742,250...38,782,282
Ensembl chr 7:38,742,051...38,782,323
|
|
G |
Ddb1 |
damage-specific DNA binding protein 1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of DDB1 mRNA |
CTD |
PMID:11056294 |
|
NCBI chr 1:226,657,561...226,683,356
Ensembl chr 1:226,657,561...226,683,347
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
affects expression increases expression multiple interactions decreases expression |
EXP ISO |
Cyclophosphamide affects the expression of DDIT3 mRNA Cyclophosphamide results in increased expression of DDIT3 mRNA; Cyclophosphamide results in increased expression of DDIT3 protein sacubitril-valsartan inhibits the reaction [Cyclophosphamide results in increased expression of DDIT3 mRNA]; sacubitril-valsartan inhibits the reaction [Cyclophosphamide results in increased expression of DDIT3 protein]; Valsartan inhibits the reaction [Cyclophosphamide results in increased expression of DDIT3 mRNA]; Valsartan inhibits the reaction [Cyclophosphamide results in increased expression of DDIT3 protein] Cyclophosphamide metabolite results in decreased expression of DDIT3 mRNA |
CTD |
PMID:18246545 PMID:24356939 PMID:32197949 |
|
NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
|
|
G |
Ddit4 |
DNA-damage-inducible transcript 4 |
affects response to substance |
ISO |
DDIT4 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr20:29,509,283...29,511,382
Ensembl chr20:29,509,289...29,511,382
|
|
G |
Deaf1 |
DEAF1 transcription factor |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of DEAF1 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 1:214,283,787...214,317,466
Ensembl chr 1:214,283,790...214,317,466
|
|
G |
Dlc1 |
DLC1 Rho GTPase activating protein |
increases expression |
ISO |
Cyclophosphamide results in increased expression of DLC1 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr16:58,776,489...59,247,752
Ensembl chr16:59,077,574...59,247,754
|
|
G |
Dnajb1 |
DnaJ heat shock protein family (Hsp40) member B1 |
affects expression increases expression |
EXP ISO |
Cyclophosphamide affects the expression of DNAJB1 mRNA Cyclophosphamide metabolite results in increased expression of DNAJB1 mRNA |
CTD |
PMID:18246545 PMID:24356939 |
|
NCBI chr19:24,747,178...24,750,919
Ensembl chr19:24,747,178...24,750,919
|
|
G |
Dnajb4 |
DnaJ heat shock protein family (Hsp40) member B4 |
increases expression |
ISO |
Cyclophosphamide metabolite results in increased expression of DNAJB4 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 2:257,394,692...257,425,344
Ensembl chr 2:257,394,818...257,425,242
|
|
G |
Dnajb6 |
DnaJ heat shock protein family (Hsp40) member B6 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of DNAJB6 protein |
CTD |
PMID:17475930 |
|
NCBI chr 4:2,711,329...2,774,969
Ensembl chr 4:2,711,385...2,774,890
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
multiple interactions increases expression decreases methylation |
ISO |
Cyclophosphamide promotes the reaction [KDM1A protein results in decreased methylation of and results in decreased degradation of DNMT1 protein] Cyclophosphamide results in increased expression of DNMT1 protein Cyclophosphamide results in decreased methylation of DNMT1 protein |
CTD |
PMID:22007908 |
|
NCBI chr 8:21,922,515...21,968,495
Ensembl chr 8:21,922,515...21,968,495
|
|
G |
Dntt |
DNA nucleotidylexotransferase |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of DNTT mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 1:260,289,626...260,321,174
Ensembl chr 1:260,289,589...260,321,320
|
|
G |
Dpf3 |
double PHD fingers 3 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of DPF3 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 6:106,660,569...106,971,310
Ensembl chr 6:106,721,349...106,971,250
|
|
G |
Dpysl4 |
dihydropyrimidinase-like 4 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of DPYSL4 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 1:211,423,022...211,438,533
Ensembl chr 1:211,423,022...211,438,531
|
|
G |
Drd1 |
dopamine receptor D1 |
affects binding |
ISO |
Cyclophosphamide binds to DRD1 protein |
CTD |
PMID:11180191 |
|
NCBI chr17:11,099,736...11,104,352
Ensembl chr17:11,101,306...11,103,541
|
|
G |
Drd2 |
dopamine receptor D2 |
affects binding |
ISO |
Cyclophosphamide binds to DRD2 protein |
CTD |
PMID:11180191 |
|
NCBI chr 8:53,678,777...53,743,643
Ensembl chr 8:53,678,777...53,743,642
|
|
G |
Dusp10 |
dual specificity phosphatase 10 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of DUSP10 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr13:104,284,660...104,321,455
Ensembl chr13:104,284,660...104,321,455
|
|
G |
Dusp2 |
dual specificity phosphatase 2 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of DUSP2 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 3:119,776,925...119,779,110
Ensembl chr 3:119,776,925...119,779,099
|
|
G |
Dzip1 |
DAZ interacting zinc finger protein 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of DZIP1 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr15:104,117,551...104,168,574
Ensembl chr15:104,117,556...104,170,958
|
|
G |
E2f3 |
E2F transcription factor 3 |
multiple interactions |
ISO |
E2F3 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr17:36,334,136...36,408,831
Ensembl chr17:36,334,147...36,408,831
|
|
G |
Eda2r |
ectodysplasin A2 receptor |
increases expression |
ISO |
Cyclophosphamide results in increased expression of EDA2R mRNA |
CTD |
PMID:21527772 |
|
NCBI chr X:66,560,200...66,602,509
Ensembl chr X:66,561,286...66,602,506
|
|
G |
Edn1 |
endothelin 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of EDN1 protein |
CTD |
PMID:17562616 PMID:18548196 |
|
NCBI chr17:22,136,814...22,143,745
Ensembl chr17:22,137,324...22,143,324
|
|
G |
Ednrb |
endothelin receptor type B |
increases expression |
ISO |
Cyclophosphamide results in increased expression of EDNRB mRNA |
CTD |
PMID:20849824 |
|
NCBI chr15:88,004,775...88,036,354
Ensembl chr15:88,006,977...88,036,354
|
|
G |
Eef2 |
eukaryotic translation elongation factor 2 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of EEF2 mRNA |
CTD |
PMID:18246545 |
|
NCBI chr 7:11,401,501...11,406,771
Ensembl chr 7:11,401,501...11,406,771
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
EGFR protein affects the susceptibility to [Cyclophosphamide co-treated with Doxorubicin co-treated with Fluorouracil] |
CTD |
PMID:15981280 |
|
NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
|
|
G |
Egr1 |
early growth response 1 |
increases expression multiple interactions decreases expression |
ISO EXP |
Cyclophosphamide results in increased expression of EGR1 mRNA 3-cyanoalanine inhibits the reaction [[N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine co-treated with Cyclophosphamide] results in increased expression of EGR1 protein]; [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine co-treated with Cyclophosphamide] results in increased expression of EGR1 protein Cyclophosphamide results in increased expression of EGR1 protein Cyclophosphamide results in decreased expression of EGR1 mRNA |
CTD |
PMID:7498375 PMID:9776515 PMID:21041162 PMID:21527772 PMID:29129814 |
|
NCBI chr18:27,657,903...27,660,101
Ensembl chr18:27,657,628...27,661,429
|
|
G |
Egr2 |
early growth response 2 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of EGR2 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr20:22,452,170...22,461,018
Ensembl chr20:22,454,463...22,459,025
|
|
G |
Egr4 |
early growth response 4 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of EGR4 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 4:117,293,620...117,296,082
Ensembl chr 4:117,293,620...117,296,082
|
|
G |
Eif1ax |
eukaryotic translation initiation factor 1A, X-linked |
multiple interactions |
ISO |
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of EIF1AX mRNA |
CTD |
PMID:16322899 |
|
NCBI chr X:37,579,959...37,595,300
Ensembl chr X:37,579,957...37,595,486
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
increases phosphorylation multiple interactions |
EXP |
Cyclophosphamide results in increased phosphorylation of EIF2AK3 protein sacubitril-valsartan inhibits the reaction [Cyclophosphamide results in increased phosphorylation of EIF2AK3 protein]; Valsartan inhibits the reaction [Cyclophosphamide results in increased phosphorylation of EIF2AK3 protein] |
CTD |
PMID:32197949 |
|
NCBI chr 4:98,648,513...98,709,695
Ensembl chr 4:98,648,545...98,709,694
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
multiple interactions |
ISO |
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of EIF4EBP1 mRNA |
CTD |
PMID:16322899 |
|
NCBI chr16:68,954,860...68,968,248
Ensembl chr16:68,954,875...68,968,248
|
|
G |
Elovl2 |
ELOVL fatty acid elongase 2 |
affects response to substance |
ISO |
ELOVL2 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr17:21,382,461...21,422,413
Ensembl chr17:21,382,455...21,422,407
|
|
G |
Emp1 |
epithelial membrane protein 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of EMP1 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 4:169,161,076...169,181,967
Ensembl chr 4:169,147,243...169,181,966
|
|
G |
Emp3 |
epithelial membrane protein 3 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of EMP3 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 1:101,900,731...101,903,948
Ensembl chr 1:101,900,733...101,903,910
|
|
G |
Epb41l2 |
erythrocyte membrane protein band 4.1-like 2 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of EPB41L2 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 1:20,881,820...21,067,713
Ensembl chr 1:20,893,995...20,962,526
|
|
G |
Ephx1 |
epoxide hydrolase 1 |
affects expression increases expression |
EXP |
Cyclophosphamide affects the expression of EPHX1 mRNA Cyclophosphamide results in increased expression of EPHX1 mRNA |
CTD |
PMID:18246545 |
|
NCBI chr13:99,271,390...99,300,580
Ensembl chr13:99,271,366...99,300,579
|
|
G |
Epo |
erythropoietin |
multiple interactions increases response to substance decreases expression |
EXP |
angelicae sinensis extract inhibits the reaction [Cyclophosphamide results in decreased expression of EPO mRNA]; Astragali compound inhibits the reaction [Cyclophosphamide results in decreased expression of EPO mRNA] EPO protein results in increased susceptibility to Cyclophosphamide |
CTD |
PMID:11245434 PMID:19627214 |
|
NCBI chr12:22,274,828...22,278,268
Ensembl chr12:22,274,828...22,278,266
|
|
G |
Erap1 |
endoplasmic reticulum aminopeptidase 1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of ERAP1 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 2:1,410,877...1,449,734
Ensembl chr 2:1,410,934...1,449,733
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
multiple interactions |
ISO |
ERBB2 affects the susceptibility to [Doxorubicin co-treated with Cyclophosphamide co-treated with docetaxel]; ERBB2 protein affects the susceptibility to [Cyclophosphamide co-treated with Doxorubicin co-treated with docetaxel]; ERBB2 protein affects the susceptibility to [Cyclophosphamide co-treated with pirarubicin co-treated with Fluorouracil]; ERBB2 protein affects the susceptibility to [Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide]; ERBB2 protein affects the susceptibility to [Fluorouracil co-treated with Epirubicin co-treated with Cyclophosphamide]; ERBB2 protein results in decreased susceptibility to [Cyclophosphamide co-treated with Thiotepa co-treated with Carboplatin] |
CTD |
PMID:9816327 PMID:15834928 PMID:15940066 PMID:16446318 PMID:16682728 PMID:17010609 |
|
NCBI chr10:86,367,596...86,391,728
Ensembl chr10:86,367,596...86,391,728
|
|
G |
Erbb4 |
erb-b2 receptor tyrosine kinase 4 |
multiple interactions |
ISO |
ERBB4 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr 9:75,021,790...76,178,936
Ensembl chr 9:75,021,790...75,528,644
|
|
G |
Ercc1 |
ERCC excision repair 1, endonuclease non-catalytic subunit |
affects expression |
EXP |
Cyclophosphamide affects the expression of ERCC1 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr 1:80,256,973...80,268,198
Ensembl chr 1:80,256,973...80,268,198
|
|
G |
Ercc2 |
ERCC excision repair 2, TFIIH core complex helicase subunit |
affects expression increases expression multiple interactions |
EXP ISO |
Cyclophosphamide affects the expression of ERCC2 mRNA Cyclophosphamide results in increased expression of ERCC2 mRNA 5-(N-methyl-N-propargylaminomethyl)-8-hydroxyquinoline inhibits the reaction [Cyclophosphamide results in increased expression of ERCC2 mRNA] |
CTD |
PMID:11906922 PMID:30760223 |
|
NCBI chr 1:80,293,574...80,307,334
Ensembl chr 1:80,293,566...80,307,344
|
|
G |
Erg |
ETS transcription factor ERG |
increases expression |
ISO |
Cyclophosphamide results in increased expression of ERG mRNA |
CTD |
PMID:17403535 |
|
NCBI chr11:35,645,317...35,749,637
Ensembl chr11:35,646,116...35,749,594
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
increases phosphorylation multiple interactions |
EXP |
Cyclophosphamide results in increased phosphorylation of ERN1 protein sacubitril-valsartan inhibits the reaction [Cyclophosphamide results in increased phosphorylation of ERN1 protein]; Valsartan inhibits the reaction [Cyclophosphamide results in increased phosphorylation of ERN1 protein] |
CTD |
PMID:32197949 |
|
NCBI chr10:94,588,555...94,682,072
Ensembl chr10:94,588,555...94,681,914
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
[Doxorubicin co-treated with Cyclophosphamide] results in increased expression of ESR1 mRNA |
CTD |
PMID:16322899 |
|
NCBI chr 1:41,192,029...41,594,799
Ensembl chr 1:41,192,824...41,594,796
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions |
ISO |
[Doxorubicin co-treated with Cyclophosphamide] results in increased expression of ESR2 mRNA |
CTD |
PMID:16322899 |
|
NCBI chr 6:99,163,953...99,214,711
Ensembl chr 6:99,164,357...99,214,251
|
|
G |
Esrra |
estrogen related receptor, alpha |
decreases expression increases expression |
EXP |
Cyclophosphamide results in decreased expression of ESRRA mRNA Cyclophosphamide results in increased expression of ESRRA mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 1:222,168,729...222,178,842
Ensembl chr 1:222,168,730...222,178,725
|
|
G |
Evi2a |
ecotropic viral integration site 2A |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of EVI2A mRNA |
CTD |
PMID:24356939 |
|
NCBI chr10:66,870,048...66,873,948
Ensembl chr10:66,870,067...66,873,948
|
|
G |
F2rl1 |
F2R like trypsin receptor 1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of F2RL1 protein |
CTD |
PMID:15643279 |
|
NCBI chr 2:25,222,324...25,235,275
Ensembl chr 2:25,222,328...25,235,275
|
|
G |
F2rl2 |
coagulation factor II (thrombin) receptor-like 2 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of F2RL2 protein |
CTD |
PMID:15643279 |
|
NCBI chr 2:26,240,385...26,245,533
Ensembl chr 2:26,240,385...26,245,533
|
|
G |
F2rl3 |
F2R like thrombin or trypsin receptor 3 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of F2RL3 protein |
CTD |
PMID:15643279 |
|
NCBI chr16:18,817,797...18,819,790
Ensembl chr16:18,814,622...18,819,833
|
|
G |
F3 |
coagulation factor III, tissue factor |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of F3 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 2:225,310,686...225,322,281
Ensembl chr 2:225,310,624...225,322,272
|
|
G |
Fam107b |
family with sequence similarity 107, member B |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of FAM107B mRNA |
CTD |
PMID:24356939 |
|
NCBI chr17:78,489,667...78,689,933
Ensembl chr17:78,489,668...78,561,613
|
|
G |
Fam234b |
family with sequence similarity 234, member B |
multiple interactions |
ISO |
FAM234B mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr 4:168,976,797...169,052,750
Ensembl chr 4:168,976,859...169,019,561
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions decreases expression increases expression |
ISO EXP |
[Cyclophosphamide co-treated with cacalol] results in decreased expression of FAS protein; [Cyclophosphamide co-treated with NAc-Sar-Gly-Val-(d-allo-Ile)-Thr-Nva-Ile-Arg-ProNEt] results in increased expression of FAS Plant Extracts inhibits the reaction [Cyclophosphamide results in increased expression of FAS mRNA] Cyclophosphamide metabolite results in decreased expression of FAS mRNA Cyclophosphamide results in increased expression of FAS mRNA; Cyclophosphamide results in increased expression of FAS protein |
CTD |
PMID:10393266 PMID:16166447 PMID:20665104 PMID:24356939 PMID:25446862 |
|
NCBI chr 1:252,589,785...252,624,790
Ensembl chr 1:252,589,785...252,624,790
|
|
G |
Faslg |
Fas ligand |
multiple interactions |
ISO |
[Cyclophosphamide co-treated with NAc-Sar-Gly-Val-(d-allo-Ile)-Thr-Nva-Ile-Arg-ProNEt] results in increased expression of FASLG |
CTD |
PMID:16166447 |
|
NCBI chr13:79,696,811...79,717,581
Ensembl chr13:79,698,445...79,705,705
|
|
G |
Fau |
FAU, ubiquitin like and ribosomal protein S30 fusion |
increases expression |
EXP |
Cyclophosphamide results in increased expression of FAU mRNA |
CTD |
PMID:11599041 |
|
NCBI chr 1:221,420,312...221,421,827
Ensembl chr 1:221,420,271...221,421,842 Ensembl chr 6:221,420,271...221,421,842
|
|
G |
Fbxo40 |
F-box protein 40 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of FBXO40 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr11:66,713,913...66,731,195
Ensembl chr11:66,713,888...66,731,198
|
|
G |
Fbxw7 |
F-box and WD repeat domain containing 7 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of FBXW7 mRNA |
CTD |
PMID:29445054 |
|
NCBI chr 2:184,230,191...184,309,805
Ensembl chr 2:184,231,260...184,309,664
|
|
G |
Fcer1g |
Fc fragment of IgE receptor Ig |
increases expression |
ISO |
Cyclophosphamide results in increased expression of FCER1G mRNA |
CTD |
PMID:21041162 |
|
NCBI chr13:89,601,894...89,606,326
Ensembl chr13:89,601,896...89,606,326
|
|
G |
Fcgr2a |
Fc fragment of IgG receptor IIa |
increases expression |
ISO |
Cyclophosphamide results in increased expression of FCGR3 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr13:91,146,878...91,163,691
Ensembl chr13:91,168,973...91,198,036 Ensembl chr13:91,168,973...91,198,036
|
|
G |
Fcgrt |
Fc fragment of IgG receptor and transporter |
increases expression |
ISO |
Cyclophosphamide results in increased expression of FCGRT mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 1:101,086,872...101,096,159
Ensembl chr 1:101,086,877...101,095,594
|
|
G |
Fhl1 |
four and a half LIM domains 1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of FHL1 mRNA |
CTD |
PMID:23558518 |
|
NCBI chr X:159,112,516...159,172,528
Ensembl chr X:159,112,880...159,172,524
|
|
G |
Fkbp1b |
FKBP prolyl isomerase 1B |
affects response to substance |
ISO |
FKBP1B protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr 6:29,975,863...29,987,252
Ensembl chr 6:29,977,797...29,987,451
|
|
G |
Fkbpl |
FKBP prolyl isomerase like |
increases expression |
ISO |
Cyclophosphamide results in increased expression of FKBPL mRNA |
CTD |
PMID:14503796 |
|
NCBI chr20:4,411,890...4,413,360
Ensembl chr20:4,411,876...4,413,366
|
|
G |
Flnc |
filamin C |
increases expression |
ISO |
Cyclophosphamide results in increased expression of FLNC mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 4:56,710,934...56,738,779
Ensembl chr 4:56,711,049...56,738,791
|
|
G |
Flt3lg |
Fms related receptor tyrosine kinase 3 ligand |
affects expression |
ISO |
Cyclophosphamide affects the expression of FLT3L mRNA |
CTD |
PMID:12624490 |
|
NCBI chr 1:101,126,006...101,131,413
Ensembl chr 1:101,124,479...101,131,413
|
|
G |
Fndc3b |
fibronectin type III domain containing 3B |
affects response to substance |
ISO |
FNDC3B protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr 2:113,109,949...113,415,171
Ensembl chr 2:113,112,902...113,345,577
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression |
ISO EXP |
Capsaicin inhibits the reaction [Cyclophosphamide results in increased expression of FOS mRNA] Cyclophosphamide results in increased expression of FOS protein alfuzosin inhibits the reaction [Cyclophosphamide results in increased expression of FOS protein]; Capsaicin inhibits the reaction [Cyclophosphamide results in increased expression of FOS protein]; resiniferatoxin inhibits the reaction [Cyclophosphamide results in increased expression of FOS protein] |
CTD |
PMID:7498375 PMID:8801120 PMID:8808730 PMID:9776515 PMID:10749792 PMID:15099680 PMID:15217452 PMID:17240043 PMID:18093676 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
Foxp3 |
forkhead box P3 |
decreases expression multiple interactions |
ISO |
Cyclophosphamide results in decreased expression of FOXP3 mRNA; Cyclophosphamide results in decreased expression of FOXP3 protein Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of FOXP3 protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of FOXP3 protein] |
CTD |
PMID:15591121 PMID:32151603 |
|
NCBI chr X:15,753,175...15,768,648
Ensembl chr X:15,753,175...15,768,522
|
|
G |
Foxp4 |
forkhead box P4 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of FOXP4 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 9:15,068,378...15,124,962
Ensembl chr 9:15,068,399...15,125,318
|
|
G |
Fpr2 |
formyl peptide receptor 2 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of FPR2 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 1:59,800,558...59,809,507
Ensembl chr 1:59,800,984...59,802,401
|
|
G |
Fscn1 |
fascin actin-bundling protein 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of FSCN1 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr12:13,655,459...13,668,595
Ensembl chr12:13,656,554...13,668,515
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
increases expression multiple interactions decreases secretion |
ISO EXP |
Cyclophosphamide results in increased expression of FSHB protein sacubitril-valsartan inhibits the reaction [Cyclophosphamide results in decreased secretion of FSHB protein]; Valsartan inhibits the reaction [Cyclophosphamide results in decreased secretion of FSHB protein] |
CTD |
PMID:6788612 PMID:25446862 PMID:32197949 |
|
NCBI chr 3:98,088,321...98,092,131
Ensembl chr 3:98,088,324...98,092,131
|
|
G |
Fshr |
follicle stimulating hormone receptor |
multiple interactions decreases expression |
ISO |
coenzyme Q10 inhibits the reaction [Cyclophosphamide results in decreased expression of FSHR mRNA] |
CTD |
PMID:31557371 |
|
NCBI chr 6:12,796,383...12,997,817
Ensembl chr 6:12,796,383...12,997,817
|
|
G |
Fyn |
FYN proto-oncogene, Src family tyrosine kinase |
increases expression |
ISO |
Cyclophosphamide results in increased expression of FYN mRNA |
CTD |
PMID:17403535 |
|
NCBI chr20:44,436,354...44,630,316
Ensembl chr20:44,436,403...44,630,317
|
|
G |
G3bp1 |
G3BP stress granule assembly factor 1 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of G3BP1 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr10:40,812,858...40,846,252
Ensembl chr10:40,812,858...40,846,252
|
|
G |
G6pc2 |
glucose-6-phosphatase catalytic subunit 2 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of G6PC2 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 3:55,464,528...55,467,170
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
increases expression affects expression |
EXP ISO |
Cyclophosphamide results in increased expression of GADD45A mRNA Cyclophosphamide affects the expression of GADD45A mRNA |
CTD |
PMID:18246545 PMID:29445054 |
|
NCBI chr 4:97,782,512...97,784,814
Ensembl chr 4:97,782,512...97,784,842
|
|
G |
Gal |
galanin and GMAP prepropeptide |
affects expression increases expression |
EXP ISO |
Cyclophosphamide affects the expression of GAL mRNA; Cyclophosphamide affects the expression of GAL protein Cyclophosphamide results in increased expression of GAL mRNA |
CTD |
PMID:16491427 PMID:17335920 PMID:18563302 |
|
NCBI chr 1:218,653,059...218,657,922
Ensembl chr 1:218,652,917...218,657,925
|
|
G |
Galc |
galactosylceramidase |
affects response to substance |
ISO |
GALC protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr 6:122,177,195...122,239,411
Ensembl chr 6:122,178,602...122,239,614
|
|
G |
Gamt |
guanidinoacetate N-methyltransferase |
multiple interactions |
ISO |
GAMT mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr 7:12,314,848...12,317,998
Ensembl chr 7:12,314,848...12,317,998
|
|
G |
Gap43 |
growth associated protein 43 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of GAP43 protein |
CTD |
PMID:9486479 PMID:10536274 |
|
NCBI chr11:58,624,198...58,717,916
Ensembl chr11:58,624,198...58,717,914
|
|
G |
Gas2 |
growth arrest-specific 2 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of GAS2 protein |
CTD |
PMID:17475930 |
|
NCBI chr 1:107,234,389...107,363,624
Ensembl chr 1:107,262,659...107,363,788
|
|
G |
Gata3 |
GATA binding protein 3 |
decreases expression multiple interactions |
ISO |
Cyclophosphamide results in decreased expression of GATA3 mRNA; Cyclophosphamide results in decreased expression of GATA3 protein Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of GATA3 protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of GATA3 protein] |
CTD |
PMID:21041162 PMID:32151603 |
|
NCBI chr17:72,419,752...72,452,043
Ensembl chr17:72,429,618...72,450,681
|
|
G |
Gbp1 |
guanylate binding protein 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of GBP1 mRNA |
CTD |
PMID:21621594 |
|
NCBI chr 2:248,343,334...248,423,402
Ensembl chr 2:248,398,917...248,409,570
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions decreases expression |
ISO |
Cyclophosphamide promotes the reaction [NFE2L2 gene mutant form results in decreased expression of GCLC protein] Cyclophosphamide results in decreased expression of GCLC mRNA; Cyclophosphamide results in decreased expression of GCLC protein |
CTD |
PMID:27633142 |
|
NCBI chr 8:85,059,051...85,097,471
Ensembl chr 8:85,059,051...85,097,468
|
|
G |
Gdnf |
glial cell derived neurotrophic factor |
increases expression |
EXP |
Cyclophosphamide results in increased expression of GDNF mRNA |
CTD |
PMID:10683293 |
|
NCBI chr 2:56,884,181...56,912,964
Ensembl chr 2:56,887,987...56,910,238
|
|
G |
Gem |
GTP binding protein overexpressed in skeletal muscle |
increases expression |
ISO |
Cyclophosphamide results in increased expression of GEM mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 5:25,339,479...25,353,661
Ensembl chr 5:25,349,928...25,353,661
|
|
G |
Gfi1 |
growth factor independent 1 transcriptional repressor |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of GFI1 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr14:3,058,035...3,073,332
Ensembl chr14:3,058,993...3,068,371
|
|
G |
Gfra1 |
GDNF family receptor alpha 1 |
multiple interactions |
ISO |
GFRA1 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr 1:279,203,046...279,572,789
|
|
G |
Gimap4 |
GTPase, IMAP family member 4 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of GIMAP4 mRNA |
CTD |
PMID:27466211 |
|
NCBI chr 4:78,320,230...78,327,144
Ensembl chr 4:78,320,190...78,327,144
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
affects expression |
EXP |
Cyclophosphamide affects the expression of GJA1 mRNA |
CTD |
PMID:10859244 |
|
NCBI chr20:37,876,650...37,889,097
Ensembl chr20:37,876,650...37,889,089
|
|
G |
Gjb1 |
gap junction protein, beta 1 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of GJB1 mRNA |
CTD |
PMID:21621594 |
|
NCBI chr X:71,272,030...71,279,973
Ensembl chr X:71,272,042...71,279,977
|
|
G |
Glis1 |
GLIS family zinc finger 1 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of GLIS1 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 5:127,043,344...127,233,395
Ensembl chr 5:127,160,495...127,233,078
|
|
G |
Glod4 |
glyoxalase domain containing 4 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of GLOD4 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr10:64,379,922...64,398,263
Ensembl chr10:64,379,921...64,398,294
|
|
G |
Glrb |
glycine receptor, beta |
increases expression |
ISO |
Cyclophosphamide results in increased expression of GLRB mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 2:179,768,040...179,842,612
Ensembl chr 2:179,769,009...179,842,547
|
|
G |
Gls |
glutaminase |
increases expression affects response to substance |
ISO |
Cyclophosphamide results in increased expression of GLS mRNA GLS protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 PMID:21527772 |
|
NCBI chr 9:54,212,622...54,284,879
Ensembl chr 9:54,212,767...54,284,872
|
|
G |
Gng12 |
G protein subunit gamma 12 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of GNG12 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 4:97,634,925...97,763,478
Ensembl chr 4:97,657,671...97,760,102
|
|
G |
Gpatch8 |
G patch domain containing 8 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of GPATCH8 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr10:90,421,443...90,501,996
Ensembl chr10:90,421,442...90,501,819
|
|
G |
Gpr137b |
G protein-coupled receptor 137B |
increases expression |
ISO |
Cyclophosphamide results in increased expression of GPR137B mRNA |
CTD |
PMID:21527772 |
|
NCBI chr17:90,670,852...90,709,003
Ensembl chr17:90,670,872...90,746,804
|
|
G |
Gpr18 |
G protein-coupled receptor 18 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of GPR18 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr15:108,323,157...108,326,907
Ensembl chr15:108,323,179...108,326,907
|
|
G |
Gpr20 |
G protein-coupled receptor 20 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of GPR20 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr 7:114,943,675...114,953,977
Ensembl chr 7:114,944,282...114,945,344
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
increases expression increases activity multiple interactions |
EXP ISO |
Cyclophosphamide results in increased expression of GPT protein Cyclophosphamide results in increased activity of GPT protein Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in increased activity of GPT protein]; ganoderic acid A inhibits the reaction [Cyclophosphamide results in increased activity of GPT protein] Rutin inhibits the reaction [Cyclophosphamide results in increased activity of GPT protein]; Vitamin E inhibits the reaction [Cyclophosphamide results in increased expression of GPT protein] |
CTD |
PMID:25753322 PMID:25779342 PMID:29753871 PMID:30506662 |
|
NCBI chr 7:117,759,083...117,761,932
Ensembl chr 7:117,759,083...117,761,931
|
|
G |
Gpt2 |
glutamic--pyruvic transaminase 2 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of GPT2 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr19:22,599,003...22,633,529
Ensembl chr19:22,590,881...22,632,071
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
decreases expression multiple interactions |
ISO |
Cyclophosphamide results in decreased expression of GPX1 mRNA Plant Extracts inhibits the reaction [Cyclophosphamide results in decreased expression of GPX1 mRNA] |
CTD |
PMID:23542512 |
|
NCBI chr 8:117,117,430...117,118,528
Ensembl chr 8:117,117,430...117,118,522
|
|
G |
Gpx3 |
glutathione peroxidase 3 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of GPX3 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr10:40,247,436...40,255,423
Ensembl chr10:40,247,436...40,255,422
|
|
G |
Gpx4 |
glutathione peroxidase 4 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of GPX4 protein |
CTD |
PMID:17475930 |
|
NCBI chr 7:12,516,357...12,519,154
Ensembl chr 7:12,516,352...12,519,154
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions decreases activity |
ISO EXP |
[[Cyclophosphamide co-treated with Cisplatin co-treated with Carmustine] results in decreased activity of GSR protein] which results in increased abundance of Glutathione Disulfide; [Cyclophosphamide co-treated with Cisplatin co-treated with Carmustine] results in decreased activity of GSR protein; Buthionine Sulfoximine promotes the reaction [Cyclophosphamide results in decreased activity of GSR protein]; Plant Extracts inhibits the reaction [Buthionine Sulfoximine promotes the reaction [Cyclophosphamide results in decreased activity of GSR protein]]; Plant Extracts inhibits the reaction [Cyclophosphamide results in decreased activity of GSR protein] Plant Extracts inhibits the reaction [Cyclophosphamide results in decreased activity of GSR protein]; Rutin inhibits the reaction [Cyclophosphamide results in decreased activity of GSR protein] |
CTD |
PMID:12114195 PMID:21772021 PMID:23542512 PMID:25446862 PMID:25753322 |
|
NCBI chr16:62,197,617...62,239,987
Ensembl chr16:62,197,617...62,241,361
|
|
G |
Gsta1 |
glutathione S-transferase alpha 1 |
multiple interactions |
ISO |
GSTA1 protein affects the metabolism of [Cyclophosphamide metabolite co-treated with Glutathione] |
CTD |
PMID:12516103 |
|
NCBI chr 9:27,366,404...27,381,004
Ensembl chr 9:27,368,272...27,452,902
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
multiple interactions |
ISO |
[GSTM1 protein co-treated with CYP2C9 protein] results in increased susceptibility to [Busulfan co-treated with Cyclophosphamide]; GSTM1 gene affects the susceptibility to [Carmustine co-treated with Cyclophosphamide co-treated with Cisplatin] |
CTD |
PMID:16087946 PMID:28744217 |
|
NCBI chr 2:210,803,869...210,809,461
Ensembl chr 2:210,803,869...210,809,306
|
|
G |
Gstm2 |
glutathione S-transferase mu 2 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of GSTM2 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr 2:210,778,041...210,782,807
Ensembl chr 2:210,720,704...210,782,856
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
multiple interactions decreases response to substance affects response to substance increases expression |
ISO EXP |
GSTP1 gene SNP results in increased susceptibility to [Carmustine co-treated with Doxorubicin co-treated with Cyclophosphamide co-treated with Melphalan] GSTP1 protein results in decreased susceptibility to Cyclophosphamide GSTP1 protein affects the susceptibility to Cyclophosphamide GSTP1 protein affects the reaction [Cyclophosphamide results in increased phosphorylation of MAPK8 protein]; Mesna inhibits the reaction [GSTP1 protein affects the reaction [Cyclophosphamide results in increased phosphorylation of MAPK8 protein]] Cyclophosphamide results in increased expression of GSTP1 mRNA; Cyclophosphamide results in increased expression of GSTP1 protein |
CTD |
PMID:10954901 PMID:12791655 PMID:16141653 PMID:16242832 PMID:19696094 |
|
NCBI chr 1:219,291,679...219,294,147
Ensembl chr 1:219,291,679...219,294,147
|
|
G |
Gtf2b |
general transcription factor IIB |
increases expression |
EXP |
Cyclophosphamide results in increased expression of GTF2B mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 2:248,709,433...248,727,741
Ensembl chr 2:248,715,281...248,727,741
|
|
G |
Gtf3c1 |
general transcription factor IIIC subunit 1 |
multiple interactions |
ISO |
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of GTF3C1 mRNA |
CTD |
PMID:16322899 |
|
NCBI chr 1:197,032,473...197,098,676
Ensembl chr 1:197,032,474...197,098,649
|
|
G |
Gusb |
glucuronidase, beta |
decreases expression increases activity multiple interactions |
EXP |
Cyclophosphamide results in decreased expression of GUSB protein Cyclophosphamide results in increased activity of GUSB protein Anthocyanins inhibits the reaction [Cyclophosphamide results in increased activity of GUSB protein]; Plant Extracts inhibits the reaction [Cyclophosphamide results in increased activity of GUSB protein] |
CTD |
PMID:17686619 PMID:25451569 |
|
NCBI chr12:30,202,066...30,215,583
Ensembl chr12:30,198,822...30,227,771
|
|
G |
Gzma |
granzyme A |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of GZMA mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 2:44,968,846...44,981,436
Ensembl chr 2:44,968,765...44,981,458
|
|
G |
Gzmb |
granzyme B |
increases expression |
ISO |
Cyclophosphamide results in increased expression of GZMB mRNA |
CTD |
PMID:15331540 |
|
NCBI chr15:35,413,862...35,417,293
Ensembl chr15:35,413,793...35,417,316
|
|
G |
H2ax |
H2A.X variant histone |
increases phosphorylation |
ISO |
Cyclophosphamide results in increased phosphorylation of H2AX protein |
CTD |
PMID:32482060 |
|
NCBI chr 8:48,665,652...48,666,981
Ensembl chr 8:48,665,652...48,666,981
|
|
G |
Hcrt |
hypocretin neuropeptide precursor |
affects localization decreases expression |
EXP |
Cyclophosphamide affects the localization of HCRT protein Cyclophosphamide results in decreased expression of HCRT mRNA |
CTD |
PMID:17881193 PMID:19666069 |
|
NCBI chr10:88,669,216...88,670,430
Ensembl chr10:88,669,214...88,670,430
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
increases expression |
ISO |
Cyclophosphamide results in increased expression of HIF1A mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 6:96,810,868...96,856,303
Ensembl chr 6:96,810,907...96,856,052
|
|
G |
Hinfp |
histone H4 transcription factor |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of HINFP mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 8:48,626,398...48,638,012
Ensembl chr 8:48,628,340...48,634,797
|
|
G |
Hm13 |
histocompatibility minor 13 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of H13 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 3:148,150,695...148,189,623
Ensembl chr 3:148,150,698...148,189,623
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 |
increases expression |
ISO |
Cyclophosphamide metabolite results in increased expression of HMGCS1 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 2:52,427,351...52,445,082
Ensembl chr 2:52,431,601...52,445,055
|
|
G |
Hmox1 |
heme oxygenase 1 |
affects expression decreases expression multiple interactions increases expression |
EXP ISO |
Cyclophosphamide affects the expression of HMOX1 mRNA Cyclophosphamide results in decreased expression of HMOX1 protein [astaxanthine co-treated with Cyclophosphamide] results in increased expression of HMOX1 protein; Hemin inhibits the reaction [Cyclophosphamide results in increased expression of HMOX1 mRNA]; Hemin promotes the reaction [Cyclophosphamide results in increased expression of HMOX1 mRNA]; Melatonin inhibits the reaction [Cyclophosphamide results in decreased expression of HMOX1 protein]; sacubitril-valsartan inhibits the reaction [Cyclophosphamide results in decreased expression of HMOX1 protein]; Valsartan inhibits the reaction [Cyclophosphamide results in decreased expression of HMOX1 protein] Cyclophosphamide results in increased expression of HMOX1 mRNA; Cyclophosphamide results in increased expression of HMOX1 protein |
CTD |
PMID:11906922 PMID:17979934 PMID:18206168 PMID:18246545 PMID:19952508 PMID:20038455 PMID:20433640 PMID:32197949 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Hmox2 |
heme oxygenase 2 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of HMOX2 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr10:10,990,034...11,035,493
Ensembl chr10:10,990,034...11,035,484
|
|
G |
Hnrnpk |
heterogeneous nuclear ribonucleoprotein K |
increases expression |
ISO EXP |
Cyclophosphamide results in increased expression of HNRNPK protein Cyclophosphamide results in increased expression of HNRNPK mRNA |
CTD |
PMID:11599041 PMID:17475930 |
|
NCBI chr17:6,664,730...6,676,753
Ensembl chr17:6,665,659...6,676,654
|
|
G |
Hoxa1 |
homeobox A1 |
affects response to substance |
ISO |
HOXA1 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr 4:82,124,358...82,127,182
Ensembl chr 4:82,125,406...82,127,066
|
|
G |
Hprt1 |
hypoxanthine phosphoribosyltransferase 1 |
increases mutagenesis |
ISO EXP |
Cyclophosphamide results in increased mutagenesis of HPRT1 gene |
CTD |
PMID:17116724 PMID:23677247 |
|
NCBI chr X:158,196,640...158,228,815
Ensembl chr X:158,197,149...158,228,749 Ensembl chr X:158,197,149...158,228,749
|
|
G |
Hsp90aa1 |
heat shock protein 90 alpha family class A member 1 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of HSP90AA1 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr 6:135,107,262...135,112,793
Ensembl chr 6:135,107,271...135,112,775 Ensembl chr 6:135,107,271...135,112,775
|
|
G |
Hsp90ab1 |
heat shock protein 90 alpha family class B member 1 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of HSP90AB1 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr 9:17,817,791...17,823,163
Ensembl chr 9:17,817,721...17,823,243
|
|
G |
Hsp90b1 |
heat shock protein 90 beta family member 1 |
decreases expression increases expression |
EXP |
Cyclophosphamide results in decreased expression of HSP90B1 mRNA Cyclophosphamide results in increased expression of HSP90B1 mRNA |
CTD |
PMID:11599041 PMID:11906922 |
|
NCBI chr 7:27,226,570...27,240,533
Ensembl chr 7:27,226,569...27,240,533
|
|
G |
Hspa1a |
heat shock protein family A (Hsp70) member 1A |
affects expression increases expression |
EXP ISO |
Cyclophosphamide affects the expression of HSPA1A mRNA Cyclophosphamide results in increased expression of HSPA1A mRNA; Cyclophosphamide results in increased expression of HSPA1A protein |
CTD |
PMID:8917683 PMID:18246545 |
|
NCBI chr20:4,875,834...4,881,751
Ensembl chr20:4,877,324...4,879,779
|
|
G |
Hspa1b |
heat shock protein family A (Hsp70) member 1B |
affects expression increases expression decreases expression |
EXP ISO |
Cyclophosphamide affects the expression of HSPA1B mRNA Cyclophosphamide metabolite results in increased expression of HSPA1B mRNA Cyclophosphamide results in decreased expression of HSPA1B mRNA |
CTD |
PMID:16141653 PMID:18246545 PMID:24356939 |
|
NCBI chr20:4,877,638...4,880,112
Ensembl chr20:2,699,712...2,701,815
|
|
G |
Hspa2 |
heat shock protein family A (Hsp70) member 2 |
affects response to substance increases expression |
ISO EXP |
HSPA2 protein affects the susceptibility to Cyclophosphamide Cyclophosphamide results in increased expression of HSPA2 mRNA |
CTD |
PMID:11599041 PMID:16217747 |
|
NCBI chr 6:99,433,575...99,436,288
Ensembl chr 6:99,433,550...99,436,289
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
decreases expression increases expression |
EXP ISO |
Cyclophosphamide results in decreased expression of HSPA5 mRNA Cyclophosphamide metabolite results in increased expression of HSPA5 mRNA |
CTD |
PMID:11906922 PMID:24356939 |
|
NCBI chr 3:13,838,304...13,842,763
Ensembl chr 3:13,838,304...13,842,762
|
|
G |
Hspa8 |
heat shock protein family A (Hsp70) member 8 |
affects response to substance |
ISO |
HSPA8 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr 8:44,989,401...44,993,261
Ensembl chr 8:44,990,014...44,993,179
|
|
G |
Hspa9 |
heat shock protein family A (Hsp70) member 9 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of HSPA9 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr18:27,731,072...27,749,235
Ensembl chr18:27,731,072...27,749,235
|
|
G |
Hspb1 |
heat shock protein family B (small) member 1 |
decreases expression increases expression |
EXP |
Cyclophosphamide results in decreased expression of HSPB1 mRNA Cyclophosphamide results in increased expression of HSPB1 mRNA |
CTD |
PMID:11599041 PMID:11906922 PMID:18246545 |
|
NCBI chr12:23,839,390...23,841,051
Ensembl chr12:23,839,399...23,841,049
|
|
G |
Hspd1 |
heat shock protein family D (Hsp60) member 1 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of HSPD1 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr 9:61,680,529...61,691,202
Ensembl chr 9:61,680,530...61,690,956
|
|
G |
Hspe1 |
heat shock protein family E (Hsp10) member 1 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of HSPE1 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr 9:61,691,246...61,724,948
Ensembl chr 9:61,692,154...61,694,599
|
|
G |
Hsph1 |
heat shock protein family H (Hsp110) member 1 |
increases expression |
ISO |
Cyclophosphamide metabolite results in increased expression of HSPH1 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr12:6,322,685...6,341,898
Ensembl chr12:6,322,668...6,341,902
|
|
G |
Hyls1 |
HYLS1, centriolar and ciliogenesis associated |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of HYLS1 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 8:36,763,470...36,772,199
Ensembl chr 8:36,763,481...36,764,422
|
|
G |
Hyou1 |
hypoxia up-regulated 1 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of HYOU1 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr 8:48,699,796...48,711,912
Ensembl chr 8:48,699,769...48,711,910
|
|
G |
Ica1 |
islet cell autoantigen 1 |
affects response to substance |
ISO |
ICA1 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:11751995 |
|
NCBI chr 4:34,635,509...34,780,187
Ensembl chr 4:34,635,506...34,780,193
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
affects response to substance |
ISO |
ICAM1 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:11591119 |
|
NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059
|
|
G |
Id2 |
inhibitor of DNA binding 2 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of ID2 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 6:44,360,077...44,361,908
Ensembl chr 6:44,348,501...44,363,915
|
|
G |
Idi1 |
isopentenyl-diphosphate delta isomerase 1 |
increases expression |
ISO |
Cyclophosphamide metabolite results in increased expression of IDI1 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr17:57,976,266...57,984,036
Ensembl chr17:57,976,268...57,984,036
|
|
G |
Ier3 |
immediate early response 3 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of IER3 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr20:3,438,798...3,440,002
Ensembl chr20:3,438,798...3,440,769
|
|
G |
Ier5 |
immediate early response 5 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of IER5 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr13:72,742,210...72,744,302
Ensembl chr13:72,742,210...72,744,303
|
|
G |
Ifit2 |
interferon-induced protein with tetratricopeptide repeats 2 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of IFIT2 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 1:252,894,663...252,900,727
Ensembl chr 1:252,894,663...252,900,726
|
|
G |
Ifng |
interferon gamma |
affects expression multiple interactions decreases secretion increases expression decreases expression |
ISO EXP |
Cyclophosphamide affects the expression of IFNG mRNA [Cyclophosphamide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA Cyclophosphamide results in decreased secretion of IFNG protein Cyclophosphamide results in increased expression of IFNG mRNA Cyclophosphamide results in decreased expression of IFNG mRNA Cyclophosphamide results in increased expression of IFNG protein (4-formyl-9-methoxy-5-methyl-naphtho(2,3-b)furan-3-yl)methyl acetate inhibits the reaction [Cyclophosphamide results in decreased secretion of IFNG protein]; Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of IFNG mRNA]; IFNG protein inhibits the reaction [Cyclophosphamide results in increased abundance of Nitric Oxide]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of IFNG mRNA]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased secretion of IFNG protein] |
CTD |
PMID:10607705 PMID:11006010 PMID:11014644 PMID:15331540 PMID:18848347 PMID:18957084 PMID:21068404 PMID:22842586 PMID:23395935 PMID:29594315 PMID:32151603 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Ifngr1 |
interferon gamma receptor 1 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of IFNGR1 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 1:15,062,380...15,080,815
Ensembl chr 1:15,062,432...15,080,907
|
|
G |
Ifrd1 |
interferon-related developmental regulator 1 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of IFRD1 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 6:60,132,025...60,151,354
Ensembl chr 6:60,132,024...60,151,420
|
|
G |
Igf2bp3 |
insulin-like growth factor 2 mRNA binding protein 3 |
affects response to substance |
ISO |
IGF2BP3 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr 4:78,744,683...78,879,457
Ensembl chr 4:78,746,547...78,879,294
|
|
G |
Igfbp3 |
insulin-like growth factor binding protein 3 |
affects response to substance decreases expression |
ISO EXP |
IGFBP3 protein affects the susceptibility to Cyclophosphamide Cyclophosphamide results in decreased expression of IGFBP3 mRNA |
CTD |
PMID:16141653 PMID:16217747 |
|
NCBI chr14:87,457,647...87,465,374
Ensembl chr14:87,457,647...87,465,374
|
|
G |
Igfbp4 |
insulin-like growth factor binding protein 4 |
multiple interactions |
ISO |
IGFBP4 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr10:86,950,555...86,962,563
Ensembl chr10:86,950,557...86,962,578
|
|
G |
Igfbp5 |
insulin-like growth factor binding protein 5 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of IGFBP5 mRNA |
CTD |
PMID:15331540 PMID:20849824 |
|
NCBI chr 9:80,154,230...80,166,813
Ensembl chr 9:80,150,211...80,167,033
|
|
G |
Igkc |
immunoglobulin kappa constant |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of IGKC mRNA |
CTD |
PMID:15331540 |
|
|
|
G |
Il10 |
interleukin 10 |
decreases expression multiple interactions increases expression |
ISO EXP |
Cyclophosphamide results in decreased expression of IL10 mRNA [Cyclophosphamide co-treated with Methotrexate co-treated with Fluorouracil] results in decreased expression of IL10 protein Anthocyanins inhibits the reaction [Cyclophosphamide results in decreased expression of IL10 protein]; Plant Extracts inhibits the reaction [Cyclophosphamide results in decreased expression of IL10 protein] Cyclophosphamide results in increased expression of IL10 mRNA Cyclophosphamide results in increased expression of IL10 protein |
CTD |
PMID:11014644 PMID:11948286 PMID:18848347 PMID:21068404 PMID:25451569 PMID:31651976 |
|
NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
|
|
G |
Il12a |
interleukin 12A |
multiple interactions |
ISO |
[Doxorubicin co-treated with Cyclophosphamide] results in decreased expression of [IL12A protein binds to IL12B protein] |
CTD |
PMID:29228376 |
|
NCBI chr 2:165,076,945...165,083,996
Ensembl chr 2:165,076,607...165,084,318
|
|
G |
Il12b |
interleukin 12B |
affects expression multiple interactions increases expression |
ISO |
Cyclophosphamide affects the expression of IL12B mRNA [Doxorubicin co-treated with Cyclophosphamide] results in decreased expression of [IL12A protein binds to IL12B protein] Cyclophosphamide results in increased expression of IL12B mRNA |
CTD |
PMID:15331540 PMID:18957084 PMID:22842586 PMID:29228376 |
|
NCBI chr10:30,034,447...30,048,774
Ensembl chr10:30,038,709...30,048,085
|
|
G |
Il13ra1 |
interleukin 13 receptor subunit alpha 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of IL13RA1 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr X:122,724,081...122,783,801
Ensembl chr X:122,724,129...122,781,479
|
|
G |
Il15 |
interleukin 15 |
multiple interactions decreases secretion |
ISO |
(4-formyl-9-methoxy-5-methyl-naphtho(2,3-b)furan-3-yl)methyl acetate inhibits the reaction [Cyclophosphamide results in decreased secretion of IL15 protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased secretion of IL15 protein] |
CTD |
PMID:23395935 |
|
NCBI chr19:23,542,606...23,624,366
Ensembl chr19:23,542,889...23,554,594
|
|
G |
Il15ra |
interleukin 15 receptor subunit alpha |
increases expression |
ISO |
Cyclophosphamide results in increased expression of IL15RA mRNA |
CTD |
PMID:21041162 |
|
NCBI chr17:70,451,861...70,481,838
Ensembl chr17:70,451,411...70,481,750
|
|
G |
Il16 |
interleukin 16 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of IL16 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 1:145,781,923...145,881,538
Ensembl chr 1:145,781,928...145,870,912
|
|
G |
Il17a |
interleukin 17A |
decreases expression multiple interactions |
ISO |
Cyclophosphamide results in decreased expression of IL17A protein Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of IL17A protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of IL17A protein] |
CTD |
PMID:21880982 PMID:32151603 |
|
NCBI chr 9:26,841,299...26,844,786
Ensembl chr 9:26,841,299...26,844,786
|
|
G |
Il18 |
interleukin 18 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of IL18 protein |
CTD |
PMID:18848347 |
|
NCBI chr 8:55,009,666...55,016,286
Ensembl chr 8:54,993,859...55,016,299
|
|
G |
Il1a |
interleukin 1 alpha |
increases expression multiple interactions affects response to substance |
ISO EXP |
Cyclophosphamide results in increased expression of IL1A mRNA [Cyclophosphamide co-treated with Methotrexate co-treated with Fluorouracil] results in decreased expression of IL1A protein Cyclophosphamide results in increased expression of IL1A protein IL1A promoter polymorphism affects the susceptibility to Cyclophosphamide |
CTD |
PMID:15331540 PMID:16636934 PMID:18848347 PMID:31651976 |
|
NCBI chr 3:121,824,712...121,836,122
Ensembl chr 3:121,825,412...121,836,086
|
|
G |
Il1b |
interleukin 1 beta |
increases expression decreases expression increases response to substance multiple interactions |
ISO EXP |
Cyclophosphamide results in increased expression of IL1B mRNA; Cyclophosphamide results in increased expression of IL1B protein Cyclophosphamide results in decreased expression of IL1B protein IL1B protein results in increased susceptibility to Cyclophosphamide [Cyclophosphamide co-treated with Methotrexate co-treated with Fluorouracil] results in decreased expression of IL1B protein; [Doxorubicin co-treated with Cyclophosphamide] results in decreased expression of IL1B protein; Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of IL1B protein]; Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in increased expression of IL1B protein]; ganoderic acid A inhibits the reaction [Cyclophosphamide results in increased expression of IL1B protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of IL1B protein]; VIP protein inhibits the reaction [Cyclophosphamide results in increased expression of IL1B protein] Anthocyanins inhibits the reaction [Cyclophosphamide results in increased expression of IL1B protein]; Bilirubin inhibits the reaction [Cyclophosphamide results in increased expression of IL1B mRNA]; Pentoxifylline inhibits the reaction [Cyclophosphamide results in increased expression of IL1B protein]; Plant Extracts inhibits the reaction [Cyclophosphamide results in increased expression of IL1B protein]; Rolipram inhibits the reaction [Cyclophosphamide results in increased expression of IL1B mRNA]; Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of IL1B protein] |
CTD |
PMID:8634684 PMID:11948286 PMID:15331540 PMID:18206168 PMID:18483878 PMID:18710439 PMID:18848347 PMID:20126887 PMID:23695977 PMID:25451569 PMID:29228376 PMID:29753871 PMID:30506662 PMID:31651976 PMID:32151603 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il1rn |
interleukin 1 receptor antagonist |
increases expression |
ISO |
Cyclophosphamide results in increased expression of IL1RN mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 3:1,449,778...1,468,624
Ensembl chr 3:1,452,644...1,468,614
|
|
G |
Il2 |
interleukin 2 |
increases expression decreases expression decreases secretion multiple interactions |
ISO EXP |
Cyclophosphamide results in increased expression of IL2 mRNA Cyclophosphamide results in decreased expression of IL2 mRNA Cyclophosphamide results in decreased secretion of IL2 protein (4-formyl-9-methoxy-5-methyl-naphtho(2,3-b)furan-3-yl)methyl acetate inhibits the reaction [Cyclophosphamide results in decreased secretion of IL2 protein]; Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of IL2 mRNA]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of IL2 mRNA]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased secretion of IL2 protein] Cyclophosphamide results in decreased expression of IL2 protein |
CTD |
PMID:11006010 PMID:11948286 PMID:18848347 PMID:23395935 PMID:32151603 |
|
NCBI chr 2:123,847,150...123,851,854
Ensembl chr 2:123,847,150...123,851,854
|
|
G |
Il21 |
interleukin 21 |
multiple interactions decreases expression |
ISO |
Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of IL21 protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of IL21 protein] |
CTD |
PMID:32151603 |
|
NCBI chr 2:123,965,021...123,972,356
Ensembl chr 2:123,965,021...123,972,356
|
|
G |
Il23a |
interleukin 23 subunit alpha |
decreases secretion decreases expression multiple interactions |
ISO |
Cyclophosphamide results in decreased secretion of IL23A protein Cyclophosphamide results in decreased expression of IL23A protein Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of IL23A protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of IL23A protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased secretion of IL23A protein] |
CTD |
PMID:23395935 PMID:32151603 |
|
NCBI chr 7:2,710,609...2,712,723
Ensembl chr 7:2,710,609...2,712,723
|
|
G |
Il3 |
interleukin 3 |
multiple interactions |
ISO |
[Cyclophosphamide co-treated with Methotrexate co-treated with Fluorouracil] results in decreased expression of IL3 protein |
CTD |
PMID:31651976 |
|
NCBI chr10:39,620,535...39,622,973
Ensembl chr10:39,620,563...39,622,973
|
|
G |
Il4 |
interleukin 4 |
decreases expression multiple interactions increases expression |
ISO EXP |
Cyclophosphamide results in decreased expression of IL4 mRNA; Cyclophosphamide results in decreased expression of IL4 protein Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of IL4 protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of IL4 protein] Cyclophosphamide results in increased expression of IL4 mRNA; Cyclophosphamide results in increased expression of IL4 protein |
CTD |
PMID:11006010 PMID:11014644 PMID:11948286 PMID:18848347 PMID:22842586 PMID:32151603 |
|
NCBI chr10:38,963,979...38,969,531
Ensembl chr10:38,963,979...38,969,531
|
|
G |
Il5 |
interleukin 5 |
increases expression |
ISO EXP |
Cyclophosphamide results in increased expression of IL5 mRNA; Cyclophosphamide results in increased expression of IL5 protein |
CTD |
PMID:11006010 PMID:18848347 |
|
NCBI chr10:39,066,716...39,069,587
Ensembl chr10:39,066,716...39,069,587
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases expression decreases secretion |
ISO EXP |
[Doxorubicin co-treated with Cyclophosphamide] results in decreased expression of IL6 protein; ganoderic acid A inhibits the reaction [Cyclophosphamide results in increased expression of IL6 protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased secretion of IL6 protein]; Sizofiran promotes the reaction [Cyclophosphamide results in increased expression of IL6 mRNA]; Sizofiran promotes the reaction [Cyclophosphamide results in increased expression of IL6 protein] Cyclophosphamide results in increased expression of IL6 mRNA; Cyclophosphamide results in increased expression of IL6 protein Pentoxifylline inhibits the reaction [Cyclophosphamide results in increased expression of IL6 protein]; Rutin inhibits the reaction [Cyclophosphamide results in increased expression of IL6 protein]; Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of IL6 protein] |
CTD |
PMID:10052129 PMID:11948286 PMID:17010015 PMID:18848347 PMID:20126887 PMID:21068404 PMID:22842586 PMID:23395935 PMID:23695977 PMID:25753322 PMID:29228376 PMID:30506662 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Ilf3 |
interleukin enhancer binding factor 3 |
multiple interactions |
ISO |
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of ILF3 mRNA |
CTD |
PMID:16322899 |
|
NCBI chr 8:22,402,877...22,440,984
Ensembl chr 8:22,402,890...22,440,885
|
|
G |
Irag2 |
inositol 1,4,5-triphosphate receptor associated 2 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of LRMP mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 4:179,402,929...179,440,792
Ensembl chr 4:179,398,621...179,440,792
|
|
G |
Irs1 |
insulin receptor substrate 1 |
multiple interactions |
ISO |
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of IRS1 mRNA |
CTD |
PMID:16322899 |
|
NCBI chr 9:88,033,668...88,086,488
Ensembl chr 9:88,033,668...88,086,488
|
|
G |
Isg15 |
ISG15 ubiquitin-like modifier |
increases expression |
ISO |
Cyclophosphamide results in increased expression of ISG15 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 5:173,624,862...173,629,124
Ensembl chr 5:173,624,310...173,626,248
|
|
G |
Isl2 |
ISL LIM homeobox 2 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of ISL2 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 8:60,117,565...60,122,716
Ensembl chr 8:60,117,729...60,122,211
|
|
G |
Itk |
IL2-inducible T-cell kinase |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of ITK mRNA |
CTD |
PMID:21041162 |
|
NCBI chr10:31,431,820...31,493,413
Ensembl chr10:31,431,809...31,493,419
|
|
G |
Jchain |
joining chain of multimeric IgA and IgM |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of JCHAIN mRNA |
CTD |
PMID:15331540 |
|
NCBI chr14:21,176,841...21,183,731
Ensembl chr14:21,177,237...21,183,542
|
|
G |
Kbtbd11 |
kelch repeat and BTB domain containing 11 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of KBTBD11 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr16:79,696,395...79,716,129
Ensembl chr16:79,696,891...79,700,992
|
|
G |
Kcnq4 |
potassium voltage-gated channel subfamily Q member 4 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of KCNQ4 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr 5:139,625,783...139,677,300
Ensembl chr 5:139,627,576...139,677,300
|
|
G |
Kdm1a |
lysine demethylase 1A |
multiple interactions increases expression |
ISO |
Cyclophosphamide promotes the reaction [KDM1A protein results in decreased methylation of and results in decreased degradation of DNMT1 protein] Cyclophosphamide results in increased expression of KDM1A protein |
CTD |
PMID:22007908 |
|
NCBI chr 5:154,909,003...154,965,171
Ensembl chr 5:154,909,003...154,965,171
|
|
G |
Kdm2a |
lysine demethylase 2A |
increases expression |
EXP |
Cyclophosphamide results in increased expression of KDM2A mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 1:219,566,130...219,642,294
Ensembl chr 1:219,566,156...219,640,294
|
|
G |
Kdm4b |
lysine demethylase 4B |
multiple interactions |
ISO |
KDM4B mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr 9:10,656,035...10,734,127
Ensembl chr 9:10,653,216...10,734,073
|
|
G |
Kdr |
kinase insert domain receptor |
decreases expression increases expression |
EXP |
Cyclophosphamide results in decreased expression of KDR mRNA; Cyclophosphamide results in decreased expression of KDR protein Cyclophosphamide results in increased expression of KDR mRNA |
CTD |
PMID:18632792 PMID:19701751 |
|
NCBI chr14:34,727,677...34,787,127
Ensembl chr14:34,727,623...34,787,183
|
|
G |
Kif21b |
kinesin family member 21B |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of KIF21B mRNA |
CTD |
PMID:24356939 |
|
NCBI chr13:52,976,505...53,026,750
Ensembl chr13:52,976,507...53,023,103
|
|
G |
Kif3a |
kinesin family member 3a |
multiple interactions |
ISO |
KIF3A mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr10:38,918,705...38,953,958
Ensembl chr10:38,918,748...38,952,785
|
|
G |
Kitlg |
KIT ligand |
affects expression increases expression multiple interactions |
ISO |
Cyclophosphamide affects the expression of KITL mRNA Cyclophosphamide results in increased expression of KITL mRNA [Cyclophosphamide co-treated with Sizofiran] results in increased expression of KITL mRNA |
CTD |
PMID:10052129 PMID:12624490 PMID:12662436 |
|
NCBI chr 7:42,269,784...42,351,054
Ensembl chr 7:42,269,784...42,351,054
|
|
G |
Klf13 |
Kruppel-like factor 13 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of KLF13 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 1:124,772,596...124,803,363
Ensembl chr 1:124,772,596...124,803,363
|
|
G |
Klf2 |
Kruppel-like factor 2 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of KLF2 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr16:19,223,087...19,225,037
Ensembl chr16:19,223,087...19,225,037
|
|
G |
Klf4 |
Kruppel like factor 4 |
decreases response to substance |
ISO |
KLF4 results in decreased susceptibility to Cyclophosphamide |
CTD |
PMID:21833590 |
|
NCBI chr 5:72,283,311...72,287,669
Ensembl chr 5:72,283,313...72,287,669
|
|
G |
Klf5 |
Kruppel-like factor 5 |
affects response to substance |
ISO |
KLF5 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr15:83,703,796...83,722,921
Ensembl chr15:83,703,791...83,722,921
|
|
G |
Krcc1 |
lysine-rich coiled-coil 1 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of KRCC1 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 4:99,133,735...99,148,236
Ensembl chr 4:99,133,842...99,146,827
|
|
G |
Krt8 |
keratin 8 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of KRT8 mRNA |
CTD |
PMID:21621594 |
|
NCBI chr 7:143,596,511...143,603,745
Ensembl chr 7:143,596,511...143,603,803
|
|
G |
Krt80 |
keratin 80 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of KRT80 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 7:142,995,715...143,015,932
Ensembl chr 7:142,994,119...143,016,040
|
|
G |
Lama5 |
laminin subunit alpha 5 |
increases expression multiple interactions |
ISO |
Cyclophosphamide results in increased expression of LAMA5 mRNA 5-(N-methyl-N-propargylaminomethyl)-8-hydroxyquinoline inhibits the reaction [Cyclophosphamide results in increased expression of LAMA5 mRNA] |
CTD |
PMID:30760223 |
|
NCBI chr 3:175,553,042...175,601,112
Ensembl chr 3:175,553,045...175,601,127
|
|
G |
Lamc2 |
laminin subunit gamma 2 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of LAMC2 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr13:70,566,643...70,632,126
Ensembl chr13:70,566,643...70,626,252
|
|
G |
Lasp1 |
LIM and SH3 protein 1 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of LASP1 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr10:85,744,662...85,785,130
Ensembl chr10:85,744,568...85,785,133
|
|
G |
Lat |
linker for activation of T cells |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of LAT mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 1:197,765,644...197,770,669
Ensembl chr 1:197,765,644...197,770,669
|
|
G |
Lck |
LCK proto-oncogene, Src family tyrosine kinase |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of LCK mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 5:147,750,976...147,779,627
Ensembl chr 5:147,750,973...147,761,983
|
|
G |
Lcn2 |
lipocalin 2 |
increases expression multiple interactions |
ISO EXP |
Cyclophosphamide results in increased expression of LCN2 mRNA [Cyclophosphamide co-treated with Mecamylamine] results in increased expression of LCN2 mRNA |
CTD |
PMID:15331540 PMID:18433785 PMID:20623750 |
|
NCBI chr 3:11,414,189...11,417,534
Ensembl chr 3:11,414,186...11,417,546
|
|
G |
Ldhb |
lactate dehydrogenase B |
affects response to substance |
ISO |
LDHB protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr 4:176,701,980...176,719,999
Ensembl chr 4:176,701,983...176,720,012
|
|
G |
Lef1 |
lymphoid enhancer binding factor 1 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of LEF1 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 2:236,232,115...236,345,061
Ensembl chr 2:236,233,239...236,345,056
|
|
G |
Lgals1 |
galectin 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of LGALS1 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 7:120,153,184...120,156,290
Ensembl chr 7:120,153,184...120,156,289
|
|
G |
Lgals7 |
galectin 7 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of LGALS7 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 1:87,044,823...87,047,223
Ensembl chr 1:87,045,335...87,047,223
|
|
G |
Lhb |
luteinizing hormone subunit beta |
decreases secretion multiple interactions |
EXP |
Cyclophosphamide results in decreased secretion of LHB protein sacubitril-valsartan inhibits the reaction [Cyclophosphamide results in decreased secretion of LHB protein]; Valsartan inhibits the reaction [Cyclophosphamide results in decreased secretion of LHB protein] |
CTD |
PMID:25446862 PMID:32197949 |
|
NCBI chr 1:101,409,992...101,413,725
Ensembl chr 1:101,410,019...101,413,724
|
|
G |
Lhx2 |
LIM homeobox 2 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of LHX2 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 3:22,628,674...22,658,447
Ensembl chr 3:22,640,545...22,658,446
|
|
G |
Limd1 |
LIM domain containing 1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of LIMD1 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 8:132,553,218...132,598,826
Ensembl chr 8:132,553,218...132,598,812
|
|
G |
Lmcd1 |
LIM and cysteine-rich domains 1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of LMCD1 mRNA |
CTD |
PMID:23558518 |
|
NCBI chr 4:144,192,989...144,252,554
Ensembl chr 4:144,192,989...144,252,551
|
|
G |
Lmnb1 |
lamin B1 |
multiple interactions |
ISO |
[Cladribine co-treated with Cyclophosphamide co-treated with Mitoxantrone] results in decreased expression of LMNB1 protein; [Cladribine co-treated with Cyclophosphamide] results in decreased expression of LMNB1 protein |
CTD |
PMID:15582267 |
|
NCBI chr18:51,785,111...51,822,264
Ensembl chr18:51,785,111...51,822,264
|
|
G |
Lonrf2 |
LON peptidase N-terminal domain and ring finger 2 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of LONRF2 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 9:45,468,001...45,506,448
Ensembl chr 9:45,466,688...45,505,767
|
|
G |
Lsg1 |
large 60S subunit nuclear export GTPase 1 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of LSG1 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr11:73,693,862...73,723,457
Ensembl chr11:73,693,814...73,723,501
|
|
G |
Ltbr |
lymphotoxin beta receptor |
increases expression |
ISO |
Cyclophosphamide results in increased expression of LTBR mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 4:157,822,838...157,829,291
Ensembl chr 4:157,822,840...157,829,241
|
|
G |
Ltf |
lactotransferrin |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of LTF mRNA |
CTD |
PMID:21621594 |
|
NCBI chr 8:119,290,416...119,313,261
Ensembl chr 8:119,290,416...119,313,261
|
|
G |
Maged1 |
MAGE family member D1 |
affects response to substance |
ISO |
MAGED1 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr X:63,803,194...63,809,715
Ensembl chr X:63,803,189...63,809,861
|
|
G |
Man2b2 |
mannosidase, alpha, class 2B, member 2 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of MAN2B2 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr14:78,939,959...78,964,961
Ensembl chr14:78,939,903...78,964,961
|
|
G |
Maoa |
monoamine oxidase A |
increases expression |
ISO |
Cyclophosphamide results in increased expression of MAOA mRNA |
CTD |
PMID:17403535 |
|
NCBI chr X:6,554,698...6,620,722
Ensembl chr X:6,554,698...6,620,722
|
|
G |
Map3k12 |
mitogen activated protein kinase kinase kinase 12 |
affects expression |
EXP |
Cyclophosphamide affects the expression of MAP3K12 mRNA |
CTD |
PMID:18246545 |
|
NCBI chr 7:144,102,275...144,120,306
Ensembl chr 7:144,102,680...144,109,116
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation multiple interactions increases expression |
ISO EXP |
Cyclophosphamide results in increased phosphorylation of MAPK1 protein Cyclophosphamide results in increased phosphorylation of and results in increased activity of MAPK1 protein; NGF protein affects the reaction [Cyclophosphamide results in increased phosphorylation of and results in increased activity of MAPK1 protein] Cyclophosphamide results in increased expression of MAPK1 mRNA; Cyclophosphamide results in increased expression of MAPK1 protein modified form |
CTD |
PMID:11599041 PMID:15733095 PMID:17110531 PMID:17409261 PMID:19638304 PMID:19696094 PMID:19996110 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
multiple interactions decreases expression affects expression |
ISO EXP |
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of MAPK14 mRNA Cyclophosphamide results in decreased expression of MAPK14 mRNA Cyclophosphamide affects the expression of MAPK14 mRNA |
CTD |
PMID:16322899 PMID:18246545 |
|
NCBI chr20:5,933,290...5,995,137
Ensembl chr20:5,933,303...5,995,137
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases expression multiple interactions increases phosphorylation |
EXP ISO |
Cyclophosphamide results in increased expression of MAPK3 protein modified form Cyclophosphamide results in increased phosphorylation of and results in increased activity of MAPK3 protein; NGF protein affects the reaction [Cyclophosphamide results in increased phosphorylation of and results in increased activity of MAPK3 protein] Cyclophosphamide results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:15733095 PMID:17110531 PMID:17409261 PMID:19638304 PMID:19696094 PMID:19996110 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mapk7 |
mitogen-activated protein kinase 7 |
multiple interactions |
EXP |
Cyclophosphamide results in increased phosphorylation of and results in increased activity of MAPK7 protein |
CTD |
PMID:17110531 |
|
NCBI chr10:47,768,592...47,775,130
Ensembl chr10:47,766,680...47,775,055 Ensembl chr10:47,766,680...47,775,055
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
increases phosphorylation multiple interactions |
ISO EXP |
Cyclophosphamide results in increased phosphorylation of MAPK8 protein Cyclophosphamide results in increased phosphorylation of and results in increased activity of MAPK8 protein; NGF protein affects the reaction [Cyclophosphamide results in increased phosphorylation of and results in increased activity of MAPK8 protein] GSTP1 protein affects the reaction [Cyclophosphamide results in increased phosphorylation of MAPK8 protein]; GSTP2 protein affects the reaction [Cyclophosphamide results in increased phosphorylation of MAPK8 protein]; Mesna inhibits the reaction [Cyclophosphamide results in increased phosphorylation of MAPK8 protein]; Mesna inhibits the reaction [GSTP1 protein affects the reaction [Cyclophosphamide results in increased phosphorylation of MAPK8 protein]]; Mesna inhibits the reaction [GSTP2 protein affects the reaction [Cyclophosphamide results in increased phosphorylation of MAPK8 protein]] |
CTD |
PMID:19696094 PMID:19996110 |
|
NCBI chr16:9,620,854...9,709,342
Ensembl chr16:9,625,177...9,709,347
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
multiple interactions |
EXP |
Cyclophosphamide results in increased phosphorylation of and results in increased activity of MAPK9 protein; NGF protein affects the reaction [Cyclophosphamide results in increased phosphorylation of and results in increased activity of MAPK9 protein] |
CTD |
PMID:19996110 |
|
NCBI chr10:35,333,859...35,374,364
Ensembl chr10:35,333,859...35,374,355
|
|
G |
Mapt |
microtubule-associated protein tau |
multiple interactions |
ISO |
MAPT mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr10:92,289,002...92,386,517
Ensembl chr10:92,288,910...92,386,517
|
|
G |
Marchf7 |
membrane associated ring-CH-type finger 7 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of MARCHF7 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 3:46,284,961...46,325,230
Ensembl chr 3:46,286,712...46,324,057
|
|
G |
Marcks |
myristoylated alanine rich protein kinase C substrate |
increases expression |
ISO |
Cyclophosphamide results in increased expression of MARCKS mRNA |
CTD |
PMID:17403535 |
|
NCBI chr20:42,966,140...42,971,838
Ensembl chr20:42,966,140...42,971,838
|
|
G |
Mcm5 |
minichromosome maintenance complex component 5 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of MCM5 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr19:14,523,482...14,561,281
Ensembl chr19:14,523,554...14,561,278
|
|
G |
Mdfic |
MyoD family inhibitor domain containing |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of MDFIC mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 4:42,202,546...42,282,499
Ensembl chr 4:42,202,838...42,282,496
|
|
G |
Med13l |
mediator complex subunit 13L |
multiple interactions |
ISO |
MED13L mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr12:43,421,317...43,576,859
Ensembl chr12:43,421,308...43,576,804
|
|
G |
Melk |
maternal embryonic leucine zipper kinase |
multiple interactions |
ISO |
MELK mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr 5:59,783,835...59,844,356
Ensembl chr 5:59,783,890...59,844,356
|
|
G |
Metrn |
meteorin, glial cell differentiation regulator |
multiple interactions |
ISO |
METRN mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr10:15,164,439...15,166,457
Ensembl chr10:15,164,439...15,166,457
|
|
G |
Mfge8 |
milk fat globule EGF and factor V/VIII domain containing |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of MFGE8 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 1:140,845,478...140,860,882
Ensembl chr 1:140,845,465...140,860,894
|
|
G |
Mgmt |
O-6-methylguanine-DNA methyltransferase |
decreases expression decreases response to substance |
ISO |
Cyclophosphamide results in decreased expression of MGMT mRNA MGMT protein results in decreased susceptibility to Cyclophosphamide |
CTD |
PMID:15741301 PMID:17403535 |
|
NCBI chr 1:209,237,255...209,464,189
Ensembl chr 1:209,237,233...209,464,190
|
|
G |
Mgst1 |
microsomal glutathione S-transferase 1 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of MGST1 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr 4:172,119,382...172,134,609
Ensembl chr 4:172,119,331...172,134,607
|
|
G |
Mif |
macrophage migration inhibitory factor |
multiple interactions |
EXP |
Cyclophosphamide affects the localization of and affects the expression of MIF protein; Cyclophosphamide promotes the reaction [MIF protein binds to CXCR4 protein] |
CTD |
PMID:19066630 |
|
NCBI chr20:13,715,219...13,732,980
Ensembl chr20:13,732,198...13,732,859
|
|
G |
Mlh1 |
mutL homolog 1 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of MLH1 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr 8:119,486,655...119,523,716
Ensembl chr 8:119,486,691...119,523,964
|
|
G |
Mmel1 |
membrane metallo-endopeptidase-like 1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of MMEL1 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 5:172,273,450...172,303,905
Ensembl chr 5:172,273,459...172,304,225
|
|
G |
Mmp11 |
matrix metallopeptidase 11 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of MMP11 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr20:13,670,051...13,678,834
Ensembl chr20:13,670,066...13,678,089
|
|
G |
Mmp3 |
matrix metallopeptidase 3 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of MMP3 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 8:5,676,608...5,698,579
Ensembl chr 8:5,676,665...5,698,579
|
|
G |
Mmp8 |
matrix metallopeptidase 8 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of MMP8 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 8:5,768,808...5,777,741
Ensembl chr 8:5,768,811...5,778,702
|
|
G |
Mnda |
myeloid cell nuclear differentiation antigen |
increases expression |
ISO |
Cyclophosphamide results in increased expression of IFI204 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr13:92,073,664...92,091,335
Ensembl chr13:92,073,668...92,089,980
|
|
G |
Mpc2 |
mitochondrial pyruvate carrier 2 |
affects response to substance |
ISO |
MPC2 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr13:83,680,527...83,700,491
Ensembl chr13:83,681,322...83,700,213
|
|
G |
Mpg |
N-methylpurine-DNA glycosylase |
affects expression |
EXP |
Cyclophosphamide affects the expression of MPG mRNA |
CTD |
PMID:11906922 |
|
NCBI chr10:15,661,768...15,667,995
Ensembl chr10:15,661,608...15,668,022
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions increases activity |
EXP |
Anthocyanins inhibits the reaction [Cyclophosphamide results in increased activity of MPO protein]; Hemin inhibits the reaction [Cyclophosphamide results in increased activity of MPO protein]; Plant Extracts inhibits the reaction [Cyclophosphamide results in increased activity of MPO protein]; Rolipram inhibits the reaction [Cyclophosphamide results in increased activity of MPO protein] |
CTD |
PMID:10749792 PMID:17979934 PMID:18710439 PMID:25451569 |
|
NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
|
|
G |
Mr1 |
major histocompatibility complex, class I-related |
increases expression |
ISO |
Cyclophosphamide results in increased expression of MR1 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr13:72,771,992...72,789,861
Ensembl chr13:72,771,984...72,789,841
|
|
G |
Ms4a3 |
membrane spanning 4-domains A3 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of MS4A3 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 1:227,979,307...227,994,210
Ensembl chr 1:227,979,481...227,992,623
|
|
G |
Msh2 |
mutS homolog 2 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of MSH2 mRNA |
CTD |
PMID:11056294 PMID:11906922 |
|
NCBI chr 6:11,215,951...11,274,916
Ensembl chr 6:11,215,963...11,274,932
|
|
G |
Msh3 |
mutS homolog 3 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of MSH3 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr 2:21,790,048...21,931,791
Ensembl chr 2:21,790,044...21,931,720
|
|
G |
Mss51 |
MSS51 mitochondrial translational activator |
increases expression |
EXP |
Cyclophosphamide results in increased expression of MSS51 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr15:4,240,203...4,252,072
Ensembl chr15:4,240,203...4,252,072
|
|
G |
Mthfd2 |
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of MTHFD2 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 4:115,004,433...115,015,965
Ensembl chr 4:115,004,448...115,015,965
|
|
G |
Mtr |
5-methyltetrahydrofolate-homocysteine methyltransferase |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of MTR mRNA |
CTD |
PMID:27281708 |
|
NCBI chr17:66,210,444...66,295,014
Ensembl chr17:66,210,461...66,295,014
|
|
G |
Muc13 |
mucin 13, cell surface associated |
increases expression |
ISO |
Cyclophosphamide results in increased expression of MUC13 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr11:70,185,757...70,223,012
Ensembl chr11:70,185,757...70,211,701
|
|
G |
Mxi1 |
MAX interactor 1, dimerization protein |
affects response to substance |
ISO |
MXI1 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr 1:274,030,748...274,090,071
Ensembl chr 1:274,030,978...274,090,071
|
|
G |
Myh10 |
myosin heavy chain 10 |
affects response to substance |
ISO |
MYH10 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr10:55,274,910...55,406,738
Ensembl chr10:55,275,411...55,406,732
|
|
G |
Naip6 |
NLR family, apoptosis inhibitory protein 6 |
multiple interactions |
ISO |
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of NAIP mRNA |
CTD |
PMID:16322899 |
|
NCBI chr 2:30,377,505...30,418,578
|
|
G |
Nampt |
nicotinamide phosphoribosyltransferase |
increases expression |
ISO |
Cyclophosphamide results in increased expression of NAMPT mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 6:52,122,085...52,156,473
Ensembl chr 6:52,122,085...52,156,472
|
|
G |
Nanos1 |
nanos C2HC-type zinc finger 1 |
increases expression |
ISO |
Cyclophosphamide metabolite results in increased expression of NANOS1 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 1:282,134,676...282,140,370
Ensembl chr 1:282,134,981...282,135,772
|
|
G |
Nasp |
nuclear autoantigenic sperm protein |
increases expression |
EXP |
Cyclophosphamide results in increased expression of NASP mRNA |
CTD |
PMID:16141653 |
|
NCBI chr 5:135,446,485...135,472,113
Ensembl chr 5:135,446,962...135,472,116
|
|
G |
Ncoa7 |
nuclear receptor coactivator 7 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of NCOA7 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 1:29,225,727...29,386,642
Ensembl chr 1:29,225,707...29,385,199
|
|
G |
Ndufs2 |
NADH:ubiquinone oxidoreductase core subunit S2 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of NDUFS2 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr13:89,606,848...89,623,506
Ensembl chr13:89,606,840...89,619,398
|
|
G |
Neto2 |
neuropilin and tolloid like 2 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of NETO2 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr19:22,450,579...22,486,530
Ensembl chr19:22,450,030...22,486,531
|
|
G |
Nfatc3 |
nuclear factor of activated T-cells 3 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of NFATC3 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr19:38,039,542...38,114,003
Ensembl chr19:38,039,564...38,114,003
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
multiple interactions increases response to substance increases expression decreases expression |
EXP ISO |
[astaxanthine co-treated with Cyclophosphamide] results in increased expression of NFE2L2 protein; Melatonin inhibits the reaction [Cyclophosphamide results in decreased expression of NFE2L2 protein] Cyclophosphamide promotes the reaction [NFE2L2 gene mutant form results in decreased expression of CAT protein]; Cyclophosphamide promotes the reaction [NFE2L2 gene mutant form results in decreased expression of GCLC protein]; Cyclophosphamide promotes the reaction [NFE2L2 gene mutant form results in decreased expression of NQO1 protein]; NFE2L2 gene mutant form inhibits the reaction [Cyclophosphamide results in increased expression of NQO1 mRNA]; NFE2L2 gene mutant form promotes the reaction [Cyclophosphamide results in decreased expression of CAT protein]; NFE2L2 gene mutant form promotes the reaction [Cyclophosphamide results in decreased expression of NQO1 protein] NFE2L2 gene mutant form results in increased susceptibility to Cyclophosphamide Cyclophosphamide results in increased expression of NFE2L2 protein |
CTD |
PMID:20038455 PMID:20433640 PMID:27633142 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Nfe2l3 |
nuclear factor, erythroid 2-like 3 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of NFE2L3 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 4:81,205,214...81,233,068
Ensembl chr 4:81,205,404...81,232,813
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
increases phosphorylation multiple interactions |
ISO |
Cyclophosphamide results in increased phosphorylation of NFKBIA protein ganoderic acid A inhibits the reaction [Cyclophosphamide results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:30506662 |
|
NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
|
|
G |
Nfkbiz |
NFKB inhibitor zeta |
increases expression |
ISO |
Cyclophosphamide results in increased expression of NFKBIZ mRNA |
CTD |
PMID:15331540 |
|
NCBI chr11:47,243,342...47,271,487
Ensembl chr11:47,243,342...47,271,487
|
|
G |
Ngf |
nerve growth factor |
multiple interactions increases expression decreases expression |
ISO EXP |
3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazoleacetic acid methyl ester inhibits the reaction [Cyclophosphamide results in increased expression of NGF protein]; Cyclophosphamide promotes the reaction [NGF results in increased expression of VEGFA mRNA]; VIP protein affects the reaction [Cyclophosphamide results in increased expression of NGF protein] Cyclophosphamide results in decreased expression of NGF protein Cyclophosphamide results in increased expression of NGF mRNA; Cyclophosphamide results in increased expression of NGF protein NGF protein affects the reaction [Cyclophosphamide results in increased phosphorylation of and results in increased activity of AKT1 protein]; NGF protein affects the reaction [Cyclophosphamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; NGF protein affects the reaction [Cyclophosphamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; NGF protein affects the reaction [Cyclophosphamide results in increased phosphorylation of and results in increased activity of MAPK8 protein]; NGF protein affects the reaction [Cyclophosphamide results in increased phosphorylation of and results in increased activity of MAPK9 protein]; rofecoxib inhibits the reaction [Cyclophosphamide results in increased expression of NGF protein] |
CTD |
PMID:10683293 PMID:16879691 PMID:18299998 PMID:18632792 PMID:19996110 PMID:20127836 |
|
NCBI chr 2:204,886,158...204,939,523
Ensembl chr 2:204,886,202...204,940,453
|
|
G |
Ngfr |
nerve growth factor receptor |
increases expression |
EXP |
Cyclophosphamide results in increased expression of NGFR mRNA; Cyclophosphamide results in increased expression of NGFR protein |
CTD |
PMID:8817519 PMID:18189308 PMID:18842820 |
|
NCBI chr10:83,389,828...83,408,061
Ensembl chr10:83,389,847...83,408,061
|
|
G |
Nid1 |
nidogen 1 |
affects response to substance |
ISO |
NID1 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr17:90,553,161...90,627,133
Ensembl chr17:90,553,394...90,627,101
|
|
G |
Nkain1 |
Sodium/potassium transporting ATPase interacting 1 |
multiple interactions |
ISO |
NKAIN1 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr 5:148,635,537...148,669,709
Ensembl chr 5:148,661,070...148,667,746
|
|
G |
Nme1 |
NME/NM23 nucleoside diphosphate kinase 1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of NME1 mRNA |
CTD |
PMID:11599041 |
|
NCBI chr10:81,657,152...81,666,542
Ensembl chr10:81,657,153...81,666,523
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions increases expression increases activity |
EXP ISO |
Bilirubin inhibits the reaction [Cyclophosphamide results in increased expression of NOS2 mRNA]; Bilirubin inhibits the reaction [Cyclophosphamide results in increased expression of NOS2 protein]; ginkgolide B inhibits the reaction [Cyclophosphamide results in increased activity of NOS2 protein]; N-((3-(aminomethyl)phenyl)methyl)ethanimidamide inhibits the reaction [Cyclophosphamide results in increased activity of NOS2 protein]; pimagedine inhibits the reaction [Cyclophosphamide results in increased activity of NOS2 protein]; rofecoxib inhibits the reaction [Cyclophosphamide results in increased expression of NOS2 protein]; Rolipram inhibits the reaction [Cyclophosphamide results in increased expression of NOS2 mRNA]; Rolipram inhibits the reaction [Cyclophosphamide results in increased expression of NOS2 protein]; Rutin inhibits the reaction [Cyclophosphamide results in increased expression of NOS2 protein]; sacubitril-valsartan inhibits the reaction [Cyclophosphamide results in increased expression of NOS2 protein]; Valsartan inhibits the reaction [Cyclophosphamide results in increased expression of NOS2 protein] Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in increased expression of NOS2 protein] Cyclophosphamide results in increased expression of NOS2 mRNA; Cyclophosphamide results in increased expression of NOS2 protein |
CTD |
PMID:9006340 PMID:10607705 PMID:11046124 PMID:15821589 PMID:16879691 PMID:18206168 PMID:18296739 PMID:18710439 PMID:19691848 PMID:21068404 PMID:25753322 PMID:29753871 PMID:32197949 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Nos3 |
nitric oxide synthase 3 |
decreases activity increases expression |
EXP |
Cyclophosphamide results in decreased activity of NOS3 protein Cyclophosphamide results in increased expression of NOS3 protein |
CTD |
PMID:9006340 PMID:16125470 |
|
NCBI chr 4:7,321,908...7,342,404
Ensembl chr 4:7,320,668...7,342,410
|
|
G |
Nppb |
natriuretic peptide B |
increases expression |
ISO |
Cyclophosphamide results in increased expression of NPPB protein |
CTD |
PMID:17562616 PMID:18548196 PMID:18999883 |
|
NCBI chr 5:164,796,176...164,797,538
Ensembl chr 5:164,796,185...164,797,531
|
|
G |
Nprl2 |
NPR2-like, GATOR1 complex subunit |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of NPRL2 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr 8:116,297,950...116,301,123
Ensembl chr 8:116,297,950...116,301,122
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
decreases expression multiple interactions increases expression |
EXP ISO |
Cyclophosphamide results in decreased expression of NQO1 mRNA; Cyclophosphamide results in decreased expression of NQO1 protein Cyclophosphamide promotes the reaction [NFE2L2 gene mutant form results in decreased expression of NQO1 protein]; NFE2L2 gene mutant form inhibits the reaction [Cyclophosphamide results in increased expression of NQO1 mRNA]; NFE2L2 gene mutant form promotes the reaction [Cyclophosphamide results in decreased expression of NQO1 protein] Cyclophosphamide results in increased expression of NQO1 protein [astaxanthine co-treated with Cyclophosphamide] results in increased expression of NQO1 protein; Melatonin inhibits the reaction [Cyclophosphamide results in decreased expression of NQO1 protein]; sacubitril-valsartan inhibits the reaction [Cyclophosphamide results in decreased expression of NQO1 protein]; Valsartan inhibits the reaction [Cyclophosphamide results in decreased expression of NQO1 protein] |
CTD |
PMID:11906922 PMID:20038455 PMID:20433640 PMID:21041162 PMID:27633142 PMID:32197949 |
|
NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of NR1H4 mRNA |
CTD |
PMID:28391356 |
|
NCBI chr 7:30,003,429...30,162,095
Ensembl chr 7:30,003,429...30,162,056
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases activity multiple interactions |
ISO |
Cyclophosphamide results in increased activity of NR1I2 protein [Cyclophosphamide results in increased activity of NR1I2 protein] which results in increased expression of ABCB1 mRNA; [Cyclophosphamide results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; Cyclophosphamide binds to and results in increased activity of NR1I2 protein; NR1I2 protein promotes the reaction [Cyclophosphamide results in increased expression of ABCB1 protein] |
CTD |
PMID:17041008 PMID:18839173 PMID:20041327 |
|
NCBI chr11:65,022,100...65,058,546
Ensembl chr11:65,022,100...65,058,545
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
multiple interactions |
ISO |
[Cyclophosphamide results in increased activity of NR1I3 protein alternative form] which results in increased expression of CYP2B6 mRNA |
CTD |
PMID:17041008 |
|
NCBI chr13:89,585,072...89,591,278
Ensembl chr13:89,586,283...89,591,277
|
|
G |
Nr2c2 |
nuclear receptor subfamily 2, group C, member 2 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of NR2C2 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 4:124,005,287...124,030,349
Ensembl chr 4:124,005,280...124,030,349
|
|
G |
Nrap |
nebulin-related anchoring protein |
increases expression |
EXP |
Cyclophosphamide results in increased expression of NRAP mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 1:277,104,519...277,181,397
Ensembl chr 1:277,104,514...277,181,414
|
|
G |
Nrdc |
nardilysin convertase |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of NRD1 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 5:128,629,949...128,694,209
Ensembl chr 5:128,629,942...128,694,060
|
|
G |
Nrg1 |
neuregulin 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of NRG1 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr16:62,969,573...64,065,063
Ensembl chr16:63,837,216...64,057,434
|
|
G |
Nrp1 |
neuropilin 1 |
decreases expression increases expression |
ISO EXP |
Cyclophosphamide results in decreased expression of NRP1 mRNA Cyclophosphamide results in increased expression of NRP1 mRNA |
CTD |
PMID:15331540 PMID:18632792 |
|
NCBI chr19:61,332,351...61,486,166
Ensembl chr19:61,332,351...61,485,858
|
|
G |
Nrp2 |
neuropilin 2 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of NRP2 mRNA |
CTD |
PMID:18632792 |
|
NCBI chr 9:69,496,875...69,609,802
Ensembl chr 9:69,497,121...69,612,087
|
|
G |
Nt5c2 |
5'-nucleotidase, cytosolic II |
increases expression |
ISO |
Cyclophosphamide results in increased expression of NT5C2 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr 1:266,652,966...266,782,935
Ensembl chr 1:266,659,519...266,782,910
|
|
G |
Ntf3 |
neurotrophin 3 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of NTF3 mRNA |
CTD |
PMID:10683293 |
|
NCBI chr 4:158,636,883...158,705,886
Ensembl chr 4:158,636,884...158,705,886
|
|
G |
Ntf4 |
neurotrophin 4 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of NTF4 mRNA |
CTD |
PMID:10683293 |
|
NCBI chr 1:101,405,314...101,408,145
Ensembl chr 1:101,405,314...101,408,145
|
|
G |
Ntrk1 |
neurotrophic receptor tyrosine kinase 1 |
multiple interactions |
EXP |
Cyclophosphamide results in increased phosphorylation of and results in increased expression of NTRK1 protein |
CTD |
PMID:12412144 |
|
NCBI chr 2:187,143,568...187,160,373
Ensembl chr 2:187,143,568...187,160,373
|
|
G |
Ntrk2 |
neurotrophic receptor tyrosine kinase 2 |
multiple interactions |
EXP |
Cyclophosphamide results in increased phosphorylation of and results in increased expression of NTRK2 protein |
CTD |
PMID:12412144 |
|
NCBI chr17:5,934,651...6,245,778
Ensembl chr17:5,933,729...6,244,676
|
|
G |
Nupl2 |
nucleoporin like 2 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of NUPL2 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 4:7,512,326...7,529,106
Ensembl chr 4:7,512,326...7,529,106
|
|
G |
Ocln |
occludin |
decreases expression multiple interactions |
ISO |
Cyclophosphamide results in decreased expression of OCLN protein Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of OCLN protein] |
CTD |
PMID:32151603 |
|
NCBI chr 2:30,527,327...30,577,218
Ensembl chr 2:30,527,715...30,577,218
|
|
G |
Odc1 |
ornithine decarboxylase 1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of ODC1 mRNA |
CTD |
PMID:11599041 |
|
NCBI chr 6:42,852,529...42,859,142
Ensembl chr 6:42,852,683...42,859,927
|
|
G |
Ogg1 |
8-oxoguanine DNA glycosylase |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of OGG1 protein |
CTD |
PMID:27032448 |
|
NCBI chr 4:145,282,828...145,289,367
Ensembl chr 4:145,282,797...145,289,326
|
|
G |
Opn3 |
opsin 3 |
affects response to substance |
ISO |
OPN3 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr13:93,716,481...93,746,994
Ensembl chr13:93,716,481...93,746,994
|
|
G |
Osm |
oncostatin M |
affects expression |
ISO |
Cyclophosphamide affects the expression of OSM mRNA |
CTD |
PMID:12624490 |
|
NCBI chr14:84,457,487...84,469,426
Ensembl chr14:84,465,515...84,470,409
|
|
G |
P2rx3 |
purinergic receptor P2X 3 |
increases expression multiple interactions |
EXP |
Cyclophosphamide results in increased expression of P2RX3 protein GR 82334 inhibits the reaction [Cyclophosphamide results in increased expression of P2RX3 protein]; Suramin inhibits the reaction [Cyclophosphamide results in increased expression of P2RX3 protein] |
CTD |
PMID:23666265 |
|
NCBI chr 3:72,403,992...72,447,801
Ensembl chr 3:72,403,993...72,447,801
|
|
G |
P2ry2 |
purinergic receptor P2Y2 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of P2RY2 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 1:166,031,228...166,045,423
Ensembl chr 1:166,031,272...166,037,424
|
|
G |
Paip1 |
poly(A) binding protein interacting protein 1 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of PAIP1 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr 2:52,300,921...52,328,212
Ensembl chr 2:52,301,798...52,328,205
|
|
G |
Pard3 |
par-3 family cell polarity regulator |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of PARD3 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr19:60,017,746...60,580,628
Ensembl chr19:60,017,746...60,580,651
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases expression increases cleavage decreases expression |
ISO EXP |
[Cladribine co-treated with Cyclophosphamide co-treated with Mitoxantrone] results in decreased expression of PARP1 protein; [Cladribine co-treated with Cyclophosphamide] results in decreased expression of PARP1 protein Cyclophosphamide results in increased expression of PARP1 mRNA Cyclophosphamide results in increased cleavage of PARP1 protein Cyclophosphamide results in decreased expression of PARP1 mRNA |
CTD |
PMID:11599041 PMID:11723234 PMID:11906922 PMID:15582267 PMID:17898787 |
|
NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
|
|
G |
Pcna |
proliferating cell nuclear antigen |
affects expression multiple interactions decreases expression increases expression |
EXP ISO |
Cyclophosphamide affects the expression of PCNA mRNA coenzyme Q10 inhibits the reaction [Cyclophosphamide results in decreased expression of PCNA mRNA] Cyclophosphamide results in decreased expression of PCNA protein Cyclophosphamide results in increased expression of PCNA mRNA |
CTD |
PMID:11056294 PMID:18246545 PMID:19701751 PMID:21041162 PMID:31557371 |
|
NCBI chr 3:124,880,698...124,884,570
Ensembl chr 3:124,880,698...124,884,570
|
|
G |
Pcsk2 |
proprotein convertase subtilisin/kexin type 2 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of PCSK2 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 3:137,618,891...137,923,385
Ensembl chr 3:137,618,898...137,925,605
|
|
G |
Pdcd4 |
programmed cell death 4 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of PDCD4 mRNA |
CTD |
PMID:21873647 |
|
NCBI chr 1:274,616,625...274,648,204
Ensembl chr 1:274,625,224...274,648,204
|
|
G |
Pdia3 |
protein disulfide isomerase family A, member 3 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of PDIA3 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr 3:113,376,983...113,400,707
Ensembl chr 3:113,376,983...113,400,707
|
|
G |
Pdia4 |
protein disulfide isomerase family A, member 4 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of PDIA4 mRNA |
CTD |
PMID:11599041 |
|
NCBI chr 4:77,470,636...77,489,535
Ensembl chr 4:77,470,636...77,489,535
|
|
G |
Peli1 |
pellino E3 ubiquitin protein ligase 1 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of PELI1 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr14:106,008,086...106,062,566
Ensembl chr14:106,008,086...106,061,641
|
|
G |
Per1 |
period circadian regulator 1 |
multiple interactions decreases expression |
ISO |
5-(N-methyl-N-propargylaminomethyl)-8-hydroxyquinoline inhibits the reaction [Cyclophosphamide results in decreased expression of PER1 mRNA] |
CTD |
PMID:30760223 |
|
NCBI chr10:55,681,761...55,696,557
Ensembl chr10:55,687,050...55,695,994
|
|
G |
Phlda2 |
pleckstrin homology-like domain, family A, member 2 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of PHLDA2 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 1:216,701,345...216,704,479
Ensembl chr 1:216,702,319...216,703,534
|
|
G |
Piga |
phosphatidylinositol glycan anchor biosynthesis, class A |
increases mutagenesis |
EXP |
Cyclophosphamide results in increased mutagenesis of PIGA |
CTD |
PMID:22923490 |
|
NCBI chr X:31,786,823...31,799,751
Ensembl chr X:31,786,194...31,799,560
|
|
G |
Pigr |
polymeric immunoglobulin receptor |
increases expression |
ISO |
Cyclophosphamide results in increased expression of PIGR mRNA |
CTD |
PMID:15331540 |
|
NCBI chr13:47,564,176...47,592,093
Ensembl chr13:47,572,219...47,591,699
|
|
G |
Pla2g4a |
phospholipase A2 group IVA |
increases expression |
ISO |
Cyclophosphamide results in increased expression of PLA2G4A mRNA |
CTD |
PMID:21041162 |
|
NCBI chr13:67,062,252...67,206,688
Ensembl chr13:66,988,937...67,206,693
|
|
G |
Plau |
plasminogen activator, urokinase |
increases expression |
ISO |
Cyclophosphamide results in increased expression of PLAU mRNA |
CTD |
PMID:21527772 |
|
NCBI chr15:3,644,296...3,650,765
Ensembl chr15:3,644,769...3,650,819
|
|
G |
Plod1 |
procollagen-lysine, 2-oxoglutarate 5-dioxygenase 1 |
multiple interactions |
ISO |
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of PLOD1 mRNA |
CTD |
PMID:16322899 |
|
NCBI chr 5:164,720,629...164,747,071
Ensembl chr 5:164,720,587...164,747,083
|
|
G |
Plod3 |
procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3 |
multiple interactions |
ISO |
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of PLOD3 mRNA |
CTD |
PMID:16322899 |
|
NCBI chr12:22,716,421...22,726,982
Ensembl chr12:22,716,423...22,726,982
|
|
G |
Pms1 |
PMS1 homolog 1, mismatch repair system component |
increases expression |
EXP |
Cyclophosphamide results in increased expression of PMS1 mRNA |
CTD |
PMID:11056294 |
|
NCBI chr 9:53,120,656...53,206,520
Ensembl chr 9:53,120,656...53,206,516
|
|
G |
Pms2 |
PMS1 homolog 2, mismatch repair system component |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of PMS2 mRNA |
CTD |
PMID:11056294 |
|
NCBI chr12:12,714,394...12,738,654
Ensembl chr12:12,714,394...12,738,641
|
|
G |
Polm |
DNA polymerase mu |
increases expression |
ISO |
Cyclophosphamide results in increased expression of POLM mRNA |
CTD |
PMID:20849824 |
|
NCBI chr14:86,069,378...86,079,327
Ensembl chr14:86,069,016...86,078,954
|
|
G |
Pomc |
proopiomelanocortin |
increases expression |
EXP |
Cyclophosphamide results in increased expression of POMC protein |
CTD |
PMID:15276878 |
|
NCBI chr 6:28,382,937...28,388,771
Ensembl chr 6:28,382,962...28,388,967
|
|
G |
Pon1 |
paraoxonase 1 |
increases activity |
EXP |
Cyclophosphamide results in increased activity of PON1 protein |
CTD |
PMID:17874068 |
|
NCBI chr 4:30,249,749...30,276,297
Ensembl chr 4:30,249,742...30,276,372
|
|
G |
Por |
cytochrome p450 oxidoreductase |
multiple interactions increases expression |
ISO EXP |
POR promotes the reaction [CYP2B6 results in increased susceptibility to Cyclophosphamide]; POR promotes the reaction [CYP2C18 results in increased susceptibility to Cyclophosphamide]; POR protein promotes the reaction [CYP2B6 protein results in increased susceptibility to Cyclophosphamide] Cyclophosphamide results in increased expression of POR mRNA |
CTD |
PMID:9766669 PMID:10919648 PMID:11599041 |
|
NCBI chr12:23,998,411...24,017,063
Ensembl chr12:23,998,411...24,046,814
|
|
G |
Postn |
periostin |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of POSTN mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 2:143,656,820...143,688,087
Ensembl chr 2:143,656,793...143,688,087
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
decreases expression multiple interactions |
ISO |
Cyclophosphamide results in decreased expression of PPARA protein Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of PPARA protein] |
CTD |
PMID:29753871 |
|
NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
decreases expression increases expression multiple interactions |
EXP |
Cyclophosphamide results in decreased expression of PPARG mRNA Cyclophosphamide results in increased expression of PPARG mRNA Plant Extracts inhibits the reaction [Cyclophosphamide results in decreased expression of PPARG mRNA] |
CTD |
PMID:25446862 PMID:27281708 |
|
NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
|
|
G |
Prdm13 |
PR/SET domain 13 |
affects expression |
EXP |
Cyclophosphamide affects the expression of PRDM13 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 5:35,821,023...35,831,897
Ensembl chr 5:35,823,983...35,831,712
|
|
G |
Prkcg |
protein kinase C, gamma |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of PRKCG mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 1:64,407,098...64,433,698
Ensembl chr 1:64,407,114...64,433,636
|
|
G |
Prlr |
prolactin receptor |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of PRLR mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 2:60,131,410...60,325,686
Ensembl chr 2:60,131,776...60,325,692
|
|
G |
Procr |
protein C receptor |
increases expression |
ISO |
Cyclophosphamide results in increased expression of PROCR mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 3:151,285,321...151,289,581
Ensembl chr 3:151,285,249...151,289,595
|
|
G |
Prss3 |
serine protease 3 |
affects response to substance |
ISO |
PRSS3 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr 4:70,614,524...70,617,998
Ensembl chr 4:70,614,524...70,617,998
|
|
G |
Prtn3 |
proteinase 3 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of PRTN3 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 7:12,643,712...12,646,951
Ensembl chr 7:12,643,516...12,646,960
|
|
G |
Psma5 |
proteasome 20S subunit alpha 5 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of PSMA5 protein |
CTD |
PMID:17475930 |
|
NCBI chr 2:211,050,344...211,073,706
Ensembl chr 2:211,050,360...211,073,714
|
|
G |
Ptcra |
pre T-cell antigen receptor alpha |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of PTCRA mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 9:16,528,970...16,539,383
Ensembl chr 9:16,529,579...16,539,472
|
|
G |
Ptger1 |
prostaglandin E receptor 1 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of PTGER1 protein |
CTD |
PMID:20346049 |
|
NCBI chr19:24,799,422...24,803,373
Ensembl chr19:24,800,072...24,803,373
|
|
G |
Ptger4 |
prostaglandin E receptor 4 |
multiple interactions increases expression |
EXP |
Botulinum Toxins, Type A inhibits the reaction [Cyclophosphamide results in increased expression of PTGER4 protein] |
CTD |
PMID:18514386 PMID:20346049 |
|
NCBI chr 2:54,951,625...54,966,470
Ensembl chr 2:54,952,821...54,963,448
|
|
G |
Ptges3 |
prostaglandin E synthase 3 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of PTGES3 mRNA |
CTD |
PMID:11599041 |
|
NCBI chr 7:2,479,267...2,497,024
Ensembl chr 7:2,479,311...2,497,013
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of PTGS1 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 3:15,560,685...15,582,339
Ensembl chr 3:15,560,712...15,582,344
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
affects response to substance multiple interactions increases expression |
ISO EXP |
PTGS2 protein affects the susceptibility to Cyclophosphamide Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in increased expression of PTGS2 protein] Cyclophosphamide results in increased expression of PTGS2 mRNA; Cyclophosphamide results in increased expression of PTGS2 protein Botulinum Toxins, Type A inhibits the reaction [Cyclophosphamide results in increased expression of PTGS2 protein]; parthenolide inhibits the reaction [Cyclophosphamide results in increased expression of PTGS2 protein]; Rutin inhibits the reaction [Cyclophosphamide results in increased expression of PTGS2 protein] |
CTD |
PMID:12388444 PMID:15331540 PMID:16217747 PMID:17537839 PMID:18514386 PMID:19303104 PMID:25753322 PMID:29753871 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Ptp4a1 |
protein tyrosine phosphatase 4A1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of PTP4A1 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 9:37,223,363...37,254,222
Ensembl chr 9:37,223,729...37,231,291 Ensembl chr 9:37,223,729...37,231,291
|
|
G |
Ptprc |
protein tyrosine phosphatase, receptor type, C |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of PTPRC mRNA |
CTD |
PMID:21041162 |
|
NCBI chr13:55,061,561...55,174,150
Ensembl chr13:55,061,562...55,173,692
|
|
G |
Pura |
purine rich element binding protein A |
increases expression |
EXP |
Cyclophosphamide results in increased expression of PURA mRNA |
CTD |
PMID:11599041 |
|
NCBI chr18:29,104,712...29,114,918
Ensembl chr18:29,110,242...29,111,156
|
|
G |
Rad50 |
RAD50 double strand break repair protein |
increases expression |
EXP |
Cyclophosphamide results in increased expression of RAD50 mRNA |
CTD |
PMID:11056294 |
|
NCBI chr10:39,002,130...39,054,042
Ensembl chr10:39,001,498...39,054,142
|
|
G |
Rad51 |
RAD51 recombinase |
decreases expression increases expression |
ISO EXP |
Cyclophosphamide results in decreased expression of RAD51 mRNA Cyclophosphamide results in increased expression of RAD51 mRNA |
CTD |
PMID:11599041 PMID:21041162 |
|
NCBI chr 3:110,918,240...110,942,920
Ensembl chr 3:110,918,243...110,942,917
|
|
G |
Rad54l |
RAD54 like |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of RAD54L mRNA |
CTD |
PMID:11056294 |
|
NCBI chr 5:134,948,511...134,978,125
Ensembl chr 5:134,948,512...134,978,125
|
|
G |
Rag1 |
recombination activating 1 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of RAG1 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 3:91,206,394...91,217,491
Ensembl chr 3:91,206,394...91,217,491
|
|
G |
Ramp1 |
receptor activity modifying protein 1 |
increases expression multiple interactions |
ISO |
Cyclophosphamide results in increased expression of RAMP1 mRNA RAMP1 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 PMID:17403535 |
|
NCBI chr 9:98,313,632...98,364,206
Ensembl chr 9:98,313,632...98,364,205
|
|
G |
Rapsn |
receptor-associated protein of the synapse |
increases expression |
EXP |
Cyclophosphamide results in increased expression of RAPSN mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 3:79,859,815...79,869,486
Ensembl chr 3:79,860,179...79,869,524
|
|
G |
Rara |
retinoic acid receptor, alpha |
increases expression |
EXP |
Cyclophosphamide results in increased expression of RARA mRNA |
CTD |
PMID:16141653 |
|
NCBI chr10:86,838,819...86,884,224
Ensembl chr10:86,860,685...86,884,210
|
|
G |
Rarg |
retinoic acid receptor, gamma |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of RARG mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 7:143,840,739...143,863,206
Ensembl chr 7:143,839,980...143,863,186
|
|
G |
Rbpms |
RNA binding protein, mRNA processing factor |
increases expression |
ISO |
Cyclophosphamide results in increased expression of RBPMS mRNA |
CTD |
PMID:17403535 |
|
NCBI chr16:61,954,569...62,109,998
Ensembl chr16:61,954,590...62,096,497
|
|
G |
Rc3h1 |
ring finger and CCCH-type domains 1 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of RC3H1 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr13:78,723,028...78,794,663
Ensembl chr13:78,722,763...78,789,266
|
|
G |
Rc3h2 |
ring finger and CCCH-type domains 2 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of RC3H2 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 3:21,621,976...21,676,789
Ensembl chr 3:21,623,041...21,670,014
|
|
G |
Reg3b |
regenerating family member 3 beta |
increases expression |
ISO EXP |
Cyclophosphamide results in increased expression of REG3A mRNA; Cyclophosphamide results in increased expression of REG3B mRNA Cyclophosphamide results in increased expression of REG3B protein |
CTD |
PMID:15331540 PMID:18295254 |
|
NCBI chr 4:109,467,272...109,470,510
Ensembl chr 4:109,467,272...109,470,510
|
|
G |
Reg3g |
regenerating family member 3 gamma |
increases expression |
ISO EXP |
Cyclophosphamide results in increased expression of REG3G mRNA Cyclophosphamide results in increased expression of REG3G protein |
CTD |
PMID:15331540 PMID:18295254 |
|
NCBI chr 4:109,529,679...109,532,234
Ensembl chr 4:109,529,679...109,532,234
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
increases expression increases phosphorylation increases activity multiple interactions |
EXP ISO |
Cyclophosphamide results in increased expression of RELA protein; Cyclophosphamide results in increased expression of RELA protein modified form Cyclophosphamide results in increased phosphorylation of RELA protein Cyclophosphamide results in increased activity of RELA protein Cyclophosphamide results in increased localization of and results in increased activity of RELA protein; Dexamethasone inhibits the reaction [Cyclophosphamide results in increased localization of and results in increased activity of RELA protein]; ganoderic acid A inhibits the reaction [Cyclophosphamide results in increased phosphorylation of RELA protein] Anthocyanins inhibits the reaction [Cyclophosphamide results in increased activity of RELA protein]; Melatonin inhibits the reaction [Cyclophosphamide results in increased expression of RELA protein]; parthenolide inhibits the reaction [Cyclophosphamide results in increased expression of RELA protein modified form]; Plant Extracts inhibits the reaction [Cyclophosphamide results in increased activity of RELA protein]; sacubitril-valsartan inhibits the reaction [Cyclophosphamide results in increased phosphorylation of RELA protein]; Valsartan inhibits the reaction [Cyclophosphamide results in increased phosphorylation of RELA protein] |
CTD |
PMID:19303104 PMID:20433640 PMID:22099998 PMID:25451569 PMID:30506662 PMID:32197949 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Rev1 |
REV1, DNA directed polymerase |
decreases response to substance |
ISO |
REV1 protein results in decreased susceptibility to Cyclophosphamide |
CTD |
PMID:21068378 |
|
NCBI chr 9:44,714,137...44,786,330
Ensembl chr 9:44,714,386...44,786,041
|
|
G |
RGD1564243 |
similar to brain Zn-finger protein |
increases expression |
EXP |
Cyclophosphamide results in increased expression of RGD1564243 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr17:45,745,442...45,746,753
|
|
G |
RGD1565844 |
similar to RIKEN cDNA 1700045I19 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of RGD1565844 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr X:32,495,573...32,496,646
Ensembl chr X:32,495,809...32,496,549
|
|
G |
Ring1 |
ring finger protein 1 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of RING1 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr20:3,812,287...3,815,834
Ensembl chr20:3,812,287...3,815,834
|
|
G |
Ripply3 |
ripply transcriptional repressor 3 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of RIPPLY3 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr11:34,557,679...34,565,776
Ensembl chr11:34,557,679...34,565,776
|
|
G |
Rnase2 |
ribonuclease A family member 2 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of RNASE2 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr15:28,154,482...28,155,291
Ensembl chr15:28,154,482...28,155,291
|
|
G |
Rnd1 |
Rho family GTPase 1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of RND1 mRNA |
CTD |
PMID:23558518 |
|
NCBI chr 7:140,349,138...140,356,209
Ensembl chr 7:140,349,138...140,356,209
|
|
G |
Rnf180 |
ring finger protein 180 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of RNF180 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 2:35,718,100...35,892,578
Ensembl chr 2:35,718,889...35,870,578
|
|
G |
Rnf216 |
ring finger protein 216 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of RNF216 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr12:13,508,429...13,631,689
Ensembl chr12:13,508,429...13,632,304
|
|
G |
Rnf44 |
ring finger protein 44 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of RNF44 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr17:10,458,036...10,472,410
Ensembl chr17:10,458,110...10,472,447
|
|
G |
Rnf5 |
ring finger protein 5 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of RNF5 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr20:4,366,244...4,368,690
Ensembl chr20:4,366,246...4,368,693
|
|
G |
Rorc |
RAR-related orphan receptor C |
decreases expression multiple interactions |
ISO |
Cyclophosphamide results in decreased expression of RORC protein Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of RORC protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of RORC protein] |
CTD |
PMID:32151603 |
|
NCBI chr 2:195,612,471...195,636,797
Ensembl chr 2:195,617,021...195,637,630
|
|
G |
Rpa1 |
replication protein A1 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of RPA1 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr10:62,140,419...62,191,518
Ensembl chr10:62,140,419...62,191,512
|
|
G |
Rpa2 |
replication protein A2 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of RPA2 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr 5:150,957,041...150,967,597
Ensembl chr 5:150,957,001...150,968,269
|
|
G |
Rps3 |
ribosomal protein S3 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of RPS3 mRNA |
CTD |
PMID:11906922 |
|
NCBI chr 1:164,435,868...164,441,167
Ensembl chr 1:164,435,878...164,441,167
|
|
G |
Rps6ka2 |
ribosomal protein S6 kinase A2 |
affects response to substance |
ISO |
RPS6KA2 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr 1:53,219,346...53,499,445
Ensembl chr 1:53,360,157...53,499,445
|
|
G |
Rraga |
Ras-related GTP binding A |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of RRAGA mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 5:104,941,067...104,942,662
Ensembl chr 5:104,941,066...104,942,662
|
|
G |
Rras2 |
RAS related 2 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of RRAS2 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 1:178,940,515...179,010,257
Ensembl chr 1:178,940,516...179,010,257
|
|
G |
Rrm1 |
ribonucleotide reductase catalytic subunit M1 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of RRM1 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 1:167,538,387...167,562,688
Ensembl chr 1:167,538,263...167,562,688
|
|
G |
Rrm2 |
ribonucleotide reductase regulatory subunit M2 |
multiple interactions |
ISO |
RRM2 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr 6:43,884,627...43,890,818
Ensembl chr 6:43,884,678...43,889,515
|
|
G |
Rrm2b |
ribonucleotide reductase regulatory TP53 inducible subunit M2B |
increases expression |
ISO |
Cyclophosphamide metabolite results in increased expression of RRM2B mRNA |
CTD |
PMID:21704725 |
|
NCBI chr 7:76,750,045...76,780,817
Ensembl chr 7:76,750,050...76,780,817
|
|
G |
RT1-CE5 |
RT1 class I, locus CE5 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of HLA-F mRNA |
CTD |
PMID:20849824 |
|
NCBI chr20:4,892,702...4,896,993
Ensembl chr20:4,892,702...4,896,991
|
|
G |
Rtel1 |
regulator of telomere elongation helicase 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of RTEL1 protein |
CTD |
PMID:17475930 |
|
NCBI chr 3:176,818,012...176,856,531
Ensembl chr 3:176,818,437...176,856,531
|
|
G |
Runx3 |
RUNX family transcription factor 3 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of RUNX3 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr 5:153,507,093...153,531,137
Ensembl chr 5:153,507,093...153,531,137
|
|
G |
Sall1 |
spalt-like transcription factor 1 |
affects response to substance |
ISO |
SALL1 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr19:23,387,737...23,405,025
Ensembl chr19:23,389,375...23,405,039
|
|
G |
Satb1 |
SATB homeobox 1 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of SATB1 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 9:2,181,135...2,277,949
Ensembl chr 9:2,190,915...2,274,629
|
|
G |
Scg3 |
secretogranin III |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of SCG3 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 8:82,582,352...82,641,536
Ensembl chr 8:82,582,352...82,641,536
|
|
G |
Scrt1 |
scratch family transcriptional repressor 1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of SCRT1 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 7:117,583,453...117,587,103
Ensembl chr 7:117,583,453...117,587,103
|
|
G |
Scube2 |
signal peptide, CUB domain and EGF like domain containing 2 |
multiple interactions |
ISO |
SCUBE2 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr 1:174,428,056...174,495,356
Ensembl chr 1:174,428,699...174,495,258
|
|
G |
Sec23a |
Sec23 homolog A, COPII coat complex component |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of SEC23A mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 6:80,059,742...80,107,340
Ensembl chr 6:80,060,916...80,107,236
|
|
G |
Serpine1 |
serpin family E member 1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of SERPINE1 mRNA |
CTD |
PMID:23558518 |
|
NCBI chr12:22,641,104...22,651,482
Ensembl chr12:22,641,104...22,651,482
|
|
G |
Sesn2 |
sestrin 2 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of SESN2 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 5:150,684,891...150,703,846
Ensembl chr 5:150,684,133...150,704,117
|
|
G |
Sfn |
stratifin |
increases expression |
ISO |
Cyclophosphamide results in increased expression of SFN mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 5:151,823,422...151,824,937
Ensembl chr 5:151,823,887...151,824,633
|
|
G |
Sgce |
sarcoglycan, epsilon |
affects response to substance |
ISO |
SGCE protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr 4:29,726,140...29,769,902
Ensembl chr 4:29,726,146...29,778,039
|
|
G |
Sgk1 |
serum/glucocorticoid regulated kinase 1 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of SGK1 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 1:24,185,451...24,302,309
Ensembl chr 1:24,185,435...24,302,298
|
|
G |
Sharpin |
SHANK-associated RH domain interactor |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of SHARPIN mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 7:117,413,151...117,417,455
Ensembl chr 7:117,413,152...117,417,363
|
|
G |
Sirt5 |
sirtuin 5 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of SIRT5 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr17:23,986,710...24,013,854
Ensembl chr17:23,986,758...24,013,881
|
|
G |
Sit1 |
signaling threshold regulating transmembrane adaptor 1 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of SIT1 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 5:58,985,912...58,987,538
Ensembl chr 5:58,985,829...58,987,760
|
|
G |
Slc22a5 |
solute carrier family 22 member 5 |
multiple interactions decreases expression |
EXP |
Carnitine inhibits the reaction [Cyclophosphamide results in decreased expression of SLC22A5 mRNA]; Carnitine inhibits the reaction [Cyclophosphamide results in decreased expression of SLC22A5 protein] Cyclophosphamide results in decreased expression of SLC22A5 mRNA; Cyclophosphamide results in decreased expression of SLC22A5 protein |
CTD |
PMID:22701146 |
|
NCBI chr10:39,201,101...39,228,090
Ensembl chr10:39,201,107...39,323,853
|
|
G |
Slc2a2 |
solute carrier family 2 member 2 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of SLC2A2 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 2:114,413,427...114,445,418
Ensembl chr 2:114,413,410...114,445,395
|
|
G |
Slc2a6 |
solute carrier family 2 member 6 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of SLC2A6 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 3:5,567,729...5,575,144
Ensembl chr 3:5,568,321...5,575,136
|
|
G |
Slc39a13 |
solute carrier family 39 member 13 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of SLC39A13 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 3:79,884,524...79,892,664
Ensembl chr 3:79,884,524...79,892,429
|
|
G |
Slc39a14 |
solute carrier family 39 member 14 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of SLC39A14 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr15:51,982,872...52,029,841
Ensembl chr15:51,982,982...52,029,816
|
|
G |
Slc39a5 |
solute carrier family 39 member 5 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of SLC39A5 mRNA; Cyclophosphamide results in increased expression of SLC39A5 protein |
CTD |
PMID:27281708 |
|
NCBI chr 7:2,813,875...2,819,917
Ensembl chr 7:2,813,875...2,819,299
|
|
G |
Slc39a6 |
solute carrier family 39 member 6 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of SLC39A6 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr18:16,523,450...16,543,992
Ensembl chr18:16,522,982...16,543,992
|
|
G |
Slc3a2 |
solute carrier family 3 member 2 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of SLC3A2 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 1:224,906,566...224,921,029
Ensembl chr 1:224,906,554...224,921,092
|
|
G |
Slc43a1 |
solute carrier family 43 member 1 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of SLC43A1 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 3:72,238,796...72,265,023
Ensembl chr 3:72,238,981...72,264,466
|
|
G |
Slc7a11 |
solute carrier family 7 member 11 |
affects expression decreases expression |
ISO |
Cyclophosphamide affects the expression of SLC7A11 mRNA Cyclophosphamide metabolite results in decreased expression of SLC7A11 mRNA |
CTD |
PMID:23824090 PMID:24356939 |
|
NCBI chr 2:139,453,774...139,528,479
Ensembl chr 2:139,453,774...139,528,162
|
|
G |
Slfn4 |
schlafen family member 4 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of SLFN4 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr10:70,411,686...70,435,162
Ensembl chr10:70,411,738...70,435,156
|
|
G |
Slit1 |
slit guidance ligand 1 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of SLIT1 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr 1:260,843,481...260,992,366
Ensembl chr 1:260,843,483...260,992,366
|
|
G |
Slpi |
secretory leukocyte peptidase inhibitor |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of SLPI mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 3:160,799,979...160,802,228
Ensembl chr 3:160,799,981...160,802,433
|
|
G |
Snx10 |
sorting nexin 10 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of SNX10 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 4:81,311,490...81,375,248
Ensembl chr 4:81,311,490...81,374,158
|
|
G |
Soat1 |
sterol O-acyltransferase 1 |
affects response to substance |
ISO |
SOAT1 protein affects the susceptibility to Cyclophosphamide |
CTD |
PMID:16217747 |
|
NCBI chr13:74,035,258...74,077,759
Ensembl chr13:74,035,080...74,077,783
|
|
G |
Socs1 |
suppressor of cytokine signaling 1 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of SOCS1 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr10:4,956,795...4,958,472
Ensembl chr10:4,957,326...4,958,461
|
|
G |
Socs7 |
suppressor of cytokine signaling 7 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of SOCS7 mRNA |
CTD |
PMID:11599041 |
|
NCBI chr10:85,301,797...85,337,971
Ensembl chr10:85,301,875...85,330,397
|
|
G |
Sod1 |
superoxide dismutase 1 |
decreases expression multiple interactions |
ISO |
Cyclophosphamide results in decreased expression of SOD1 mRNA [Doxorubicin co-treated with Cyclophosphamide] results in increased expression of SOD1 protein; Plant Extracts inhibits the reaction [Cyclophosphamide results in decreased expression of SOD1 mRNA] |
CTD |
PMID:23542512 PMID:29228376 |
|
NCBI chr11:30,363,282...30,368,858
Ensembl chr11:30,363,280...30,368,862
|
|
G |
Sod2 |
superoxide dismutase 2 |
increases expression affects response to substance decreases expression |
ISO EXP |
Cyclophosphamide results in increased expression of SOD2 mRNA SOD2 polymorphism affects the susceptibility to Cyclophosphamide Cyclophosphamide results in decreased expression of SOD2 mRNA |
CTD |
PMID:11599041 PMID:11906922 PMID:15331540 PMID:20309628 |
|
NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
|
|
G |
Sord |
sorbitol dehydrogenase |
decreases activity multiple interactions |
EXP |
Cyclophosphamide results in decreased activity of SORD protein Plant Extracts inhibits the reaction [Cyclophosphamide results in decreased activity of SORD protein] |
CTD |
PMID:25446862 |
|
NCBI chr 3:114,176,127...114,207,368
Ensembl chr 3:114,176,309...114,207,366
|
|
G |
Sp2 |
Sp2 transcription factor |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of SP2 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr10:84,890,930...84,920,886
Ensembl chr10:84,890,932...84,920,886
|
|
G |
Sparc |
secreted protein acidic and cysteine rich |
decreases expression increases expression |
ISO |
Cyclophosphamide results in decreased expression of SPARC mRNA Cyclophosphamide results in increased expression of SPARC mRNA |
CTD |
PMID:15331540 PMID:17403535 |
|
NCBI chr10:40,742,390...40,764,232
Ensembl chr10:40,742,400...40,764,185
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
affects response to substance increases expression affects expression |
ISO EXP |
SPP1 protein affects the susceptibility to Cyclophosphamide Cyclophosphamide results in increased expression of SPP1 mRNA Cyclophosphamide affects the expression of SPP1 mRNA |
CTD |
PMID:16217747 PMID:20623750 PMID:23558518 |
|
NCBI chr14:6,673,686...6,679,965
Ensembl chr14:6,673,686...6,679,901
|
|
G |
Srek1ip1 |
SREK1-interacting protein 1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of SREK1IP1 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr 2:34,923,187...34,940,410
|
|
G |
Srm |
spermidine synthase |
multiple interactions |
ISO |
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of SRM mRNA |
CTD |
PMID:16322899 |
|
NCBI chr 5:165,405,168...165,408,325
Ensembl chr 5:165,405,168...165,408,320 Ensembl chr 3:165,405,168...165,408,320
|
|
G |
Ssrp1 |
structure specific recognition protein 1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of SSRP1 mRNA |
CTD |
PMID:11599041 |
|
NCBI chr 3:72,447,516...72,457,621
Ensembl chr 3:72,447,537...72,457,649
|
|
G |
St13 |
ST13, Hsp70 interacting protein |
increases expression |
EXP |
Cyclophosphamide results in increased expression of ST13 mRNA |
CTD |
PMID:11599041 |
|
NCBI chr 7:122,585,770...122,635,731
Ensembl chr 7:122,585,771...122,635,731
|
|
G |
St14 |
ST14 transmembrane serine protease matriptase |
multiple interactions |
ISO |
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of ST14 mRNA |
CTD |
PMID:16322899 |
|
NCBI chr 8:32,240,113...32,280,813
Ensembl chr 8:32,240,133...32,280,869
|
|
G |
Stat1 |
signal transducer and activator of transcription 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of STAT1 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 9:54,287,540...54,327,958
Ensembl chr 9:54,287,541...54,484,533
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
increases phosphorylation decreases phosphorylation |
EXP ISO |
Cyclophosphamide results in increased phosphorylation of STAT3 protein Cyclophosphamide results in decreased phosphorylation of STAT3 protein |
CTD |
PMID:19625377 PMID:21880982 |
|
NCBI chr10:88,790,401...88,842,263
Ensembl chr10:88,790,408...88,842,233
|
|
G |
Stat5b |
signal transducer and activator of transcription 5B |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of STAT5B mRNA |
CTD |
PMID:21041162 |
|
NCBI chr10:88,686,207...88,712,313
Ensembl chr10:88,686,207...88,754,829
|
|
G |
Stip1 |
stress-induced phosphoprotein 1 |
decreases expression |
ISO EXP |
Cyclophosphamide results in decreased expression of STIP1 mRNA |
CTD |
PMID:11906922 PMID:15331540 |
|
NCBI chr 1:222,274,133...222,293,139
Ensembl chr 1:222,274,133...222,293,148
|
|
G |
Stk39 |
serine threonine kinase 39 |
multiple interactions |
ISO |
[Doxorubicin co-treated with Cyclophosphamide] affects the expression of STK39 mRNA |
CTD |
PMID:16322899 |
|
NCBI chr 3:54,359,449...54,625,702
Ensembl chr 3:54,359,451...54,625,414
|
|
G |
Stk4 |
serine/threonine kinase 4 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of STK4 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 3:160,467,552...160,546,540
Ensembl chr 3:160,467,552...160,546,540
|
|
G |
Stmn3 |
stathmin 3 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of STMN3 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 3:176,808,016...176,816,108
Ensembl chr 3:176,808,017...176,816,162
|
|
G |
Stom |
stomatin |
increases expression |
ISO |
Cyclophosphamide results in increased expression of STOM mRNA |
CTD |
PMID:21527772 |
|
NCBI chr 3:14,515,576...14,538,199
Ensembl chr 3:14,514,868...14,538,241
|
|
G |
Sun1 |
Sad1 and UNC84 domain containing 1 |
decreases expression |
EXP |
Cyclophosphamide results in decreased expression of SUN1 mRNA |
CTD |
PMID:27281708 |
|
NCBI chr12:17,488,482...17,533,334
Ensembl chr12:17,488,487...17,522,534
|
|
G |
Tac1 |
tachykinin, precursor 1 |
multiple interactions increases expression increases secretion affects expression |
EXP ISO |
Botulinum Toxins, Type A inhibits the reaction [Cyclophosphamide results in increased secretion of TAC1 protein] Cyclophosphamide results in increased expression of TAC1 protein Cyclophosphamide affects the expression of TAC1 mRNA |
CTD |
PMID:11312054 PMID:18184328 PMID:18563302 PMID:22842586 |
|
NCBI chr 4:33,638,853...33,646,819
Ensembl chr 4:33,638,709...33,646,819
|
|
G |
Tacr1 |
tachykinin receptor 1 |
multiple interactions increases expression decreases response to substance |
ISO EXP |
[alpha-amyrin co-treated with beta-amyrin] inhibits the reaction [Cyclophosphamide results in increased expression of TACR1 protein] GR 82334 inhibits the reaction [Cyclophosphamide results in increased expression of TACR1 protein]; Suramin inhibits the reaction [Cyclophosphamide results in increased expression of TACR1 protein] TACR1 gene mutant form results in decreased susceptibility to Cyclophosphamide |
CTD |
PMID:10854767 PMID:18210232 PMID:23666265 |
|
NCBI chr 4:113,247,236...113,416,139
Ensembl chr 4:113,247,795...113,414,504
|
|
G |
Tafa5 |
TAFA chemokine like family member 5 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of TAFA5 mRNA |
CTD |
PMID:21621594 |
|
NCBI chr 7:128,500,009...128,728,834
Ensembl chr 7:128,500,011...128,728,928
|
|
G |
Tap1 |
transporter 1, ATP binding cassette subfamily B member |
increases expression |
ISO |
Cyclophosphamide results in increased expression of TAP1 mRNA |
CTD |
PMID:21527772 |
|
NCBI chr20:3,979,302...3,989,669
Ensembl chr20:3,979,035...3,989,669
|
|
G |
Tat |
tyrosine aminotransferase |
affects expression decreases expression |
EXP |
Cyclophosphamide affects the expression of TAT mRNA Cyclophosphamide results in decreased expression of TAT mRNA |
CTD |
PMID:18246545 |
|
NCBI chr19:41,675,639...41,686,195
Ensembl chr19:41,675,355...41,686,229
|
|
G |
Tbx21 |
T-box transcription factor 21 |
multiple interactions decreases expression |
ISO |
Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of TBX21 protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of TBX21 protein] |
CTD |
PMID:32151603 |
|
NCBI chr10:85,032,799...85,049,331
Ensembl chr10:85,032,799...85,049,331
|
|
G |
Tcf7 |
transcription factor 7 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of TCF7 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr10:37,616,033...37,646,027
Ensembl chr10:37,617,279...37,645,802
|
|
G |
Tcp1 |
t-complex 1 |
decreases expression increases expression |
EXP |
Cyclophosphamide results in decreased expression of TCP1 mRNA Cyclophosphamide results in increased expression of TCP1 mRNA |
CTD |
PMID:11599041 PMID:11906922 |
|
NCBI chr 1:48,025,664...48,033,343
Ensembl chr 1:48,025,663...48,033,396
|
|
G |
Tex30 |
testis expressed 30 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of TEX30 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 9:50,858,737...50,868,238
Ensembl chr 9:50,858,737...50,868,238
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
increases expression increases secretion multiple interactions affects expression |
ISO EXP |
Cyclophosphamide results in increased expression of TGFB1 mRNA Cyclophosphamide results in increased secretion of TGFB1 protein Cyclophosphamide results in increased expression of and results in increased activity of TGFB1 protein Cyclophosphamide affects the expression of TGFB1 mRNA DCN protein inhibits the reaction [TGFB1 protein results in decreased susceptibility to [Cyclophosphamide co-treated with Cisplatin co-treated with Melphalan co-treated with Thiotepa]]; TGFB1 protein results in decreased susceptibility to [Cyclophosphamide co-treated with Cisplatin co-treated with Melphalan co-treated with Thiotepa] |
CTD |
PMID:9509296 PMID:12624490 PMID:19691848 PMID:21068404 |
|
NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
|
|
G |
Tgfb2 |
transforming growth factor, beta 2 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of TGFB2 mRNA |
CTD |
PMID:23558518 |
|
NCBI chr13:105,039,639...105,142,010
Ensembl chr13:105,039,853...105,141,030
|
|
G |
Tgfb3 |
transforming growth factor, beta 3 |
multiple interactions decreases expression |
ISO |
Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of TGFB3 protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of TGFB3 protein] |
CTD |
PMID:32151603 |
|
NCBI chr 6:109,913,757...109,936,217
Ensembl chr 6:109,913,757...109,935,533
|
|
G |
Tgfbr2 |
transforming growth factor, beta receptor 2 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of TGFBR2 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 8:124,310,288...124,399,345
Ensembl chr 8:124,312,754...124,399,494
|
|
G |
Thbs1 |
thrombospondin 1 |
increases expression multiple interactions |
EXP ISO |
Cyclophosphamide results in increased expression of THBS1 protein Cyclophosphamide results in increased expression of THBS1 mRNA axitinib inhibits the reaction [Cyclophosphamide results in increased expression of THBS1 protein] |
CTD |
PMID:15331540 PMID:18202011 |
|
NCBI chr 3:109,862,120...109,873,466
Ensembl chr 3:109,862,117...109,873,466
|
|
G |
Thnsl2 |
threonine synthase-like 2 |
multiple interactions |
ISO |
THNSL2 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] |
CTD |
PMID:16896004 |
|
NCBI chr 4:98,976,559...98,997,187
Ensembl chr 4:98,976,550...98,995,590
|
|
G |
Thy1 |
Thy-1 cell surface antigen |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of THY1 mRNA |
CTD |
PMID:21041162 |
|
NCBI chr 8:48,382,121...48,387,271
Ensembl chr 8:48,382,121...48,386,935
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
increases expression |
EXP |
Cyclophosphamide results in increased expression of TIMP1 mRNA |
CTD |
PMID:23558518 |
|
NCBI chr X:1,364,771...1,369,451
Ensembl chr X:1,364,786...1,369,384
|
|
G |
Tjp1 |
tight junction protein 1 |
multiple interactions decreases expression |
EXP ISO |
Anthocyanins inhibits the reaction [Cyclophosphamide results in decreased expression of TJP1 protein]; Plant Extracts inhibits the reaction [Cyclophosphamide results in decreased expression of TJP1 protein] Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of TJP1 protein]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of TJP1 protein] |
CTD |
PMID:25451569 PMID:32151603 |
|
NCBI chr 1:126,146,489...126,515,359
Ensembl chr 1:126,146,489...126,227,469
|
|
G |
Tk1 |
thymidine kinase 1 |
increases mutagenesis |
ISO |
Cyclophosphamide metabolite results in increased mutagenesis of TK1 gene |
CTD |
PMID:32087850 |
|
NCBI chr10:106,817,556...106,828,888
Ensembl chr10:106,817,601...106,828,884
|
|
G |
Tlr2 |
toll-like receptor 2 |
decreases expression multiple interactions |
ISO |
Cyclophosphamide results in decreased expression of TLR2 mRNA Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of TLR2 mRNA]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of TLR2 mRNA] |
CTD |
PMID:32151603 |
|
NCBI chr 2:182,840,171...182,846,061
Ensembl chr 2:182,840,727...182,846,061
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions decreases expression |
ISO |
Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of TLR4 mRNA] |
CTD |
PMID:32151603 |
|
NCBI chr 5:82,587,424...82,601,056
Ensembl chr 5:82,587,420...82,601,052
|
|
G |
Tlr6 |
toll-like receptor 6 |
decreases expression multiple interactions |
ISO |
Cyclophosphamide results in decreased expression of TLR6 mRNA Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of TLR6 mRNA]; Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of TLR6 mRNA] |
CTD |
PMID:32151603 |
|
NCBI chr14:45,024,351...45,041,188
Ensembl chr14:45,024,351...45,046,446
|
|
G |
Tlr9 |
toll-like receptor 9 |
multiple interactions increases expression |
ISO |
Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in increased expression of TLR9 protein] |
CTD |
PMID:29753871 |
|
NCBI chr 8:114,916,122...114,920,171
Ensembl chr 8:114,916,122...114,920,171
|
|
G |
Tm4sf1 |
transmembrane 4 L six family member 1 |
increases expression |
ISO |
Cyclophosphamide results in increased expression of TM4SF1 mRNA |
CTD |
PMID:17403535 |
|
NCBI chr 2:147,382,866...147,392,062
Ensembl chr 2:147,382,866...147,392,062
|
|
G |
Tm6sf1 |
transmembrane 6 superfamily member 1 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of TM6SF1 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 1:143,657,607...143,703,829
Ensembl chr 1:143,661,521...143,703,759
|
|
G |
Tmed3 |
transmembrane p24 trafficking protein 3 |
decreases expression |
ISO |
Cyclophosphamide results in decreased expression of TMED3 mRNA |
CTD |
PMID:15331540 |
|
NCBI chr 8:97,075,194...97,083,107
Ensembl chr 8:97,075,160...97,083,120
|
|
G |
Tmeff1 |
transmembrane protein with EGF-like and two follistatin-like domains 1 |
affects response to substance decreases expression |
ISO EXP |
TMEFF1 protein affects the susceptibility to Cyclophosphamide Cyclophosphamide results in decreased expression of TMEFF1 mRNA |
CTD |
PMID:16217747 PMID:27466211 |
|
NCBI chr 5:64,326,733...64,412,531
Ensembl chr 5:64,326,733...64,412,523
|
|
G |
Tmem267 |
transmembrane protein 267 |
decreases expression |
ISO |
Cyclophosphamide metabolite results in decreased expression of TMEM267 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 2:52,356,449...52,366,075
Ensembl chr 2:52,358,097...52,366,667
|
|
G |
Tmprss2 |
transmembrane serine protease 2 |
increases expression |
ISO EXP |
Cyclophosphamide results in increased expression of TMPRSS2 mRNA |
CTD |
PMID:32808185 |
|
NCBI chr11:38,063,914...38,103,406
Ensembl chr11:38,063,915...38,103,290
|
|
G |
Tnf |
tumor necrosis factor |
affects expression decreases expression multiple interactions increases expression decreases response to substance increases response to substance |
ISO EXP |
Cyclophosphamide affects the expression of TNF mRNA Cyclophosphamide results in decreased expression of TNF mRNA [Cyclophosphamide co-treated with Methotrexate co-treated with Fluorouracil] results in decreased expression of TNF protein; Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of TNF mRNA]; Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in increased expression of TNF protein]; ganoderic acid A inhibits the reaction [Cyclophosphamide results in increased expression of TNF protein] Cyclophosphamide results in increased expression of TNF mRNA; Cyclophosphamide results in increased expression of TNF protein Anthocyanins inhibits the reaction [Cyclophosphamide results in increased expression of TNF protein]; Curcumin inhibits the reaction [Cyclophosphamide results in increased expression of TNF protein]; Pentoxifylline inhibits the reaction [Cyclophosphamide results in increased expression of TNF protein]; Plant Extracts inhibits the reaction [Cyclophosphamide results in increased expression of TNF protein]; Rolipram inhibits the reaction [Cyclophosphamide results in increased expression of TNF mRNA]; Rutin inhibits the reaction [Cyclophosphamide results in increased expression of TNF protein]; Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of TNF protein]; thymoquinone inhibits the reaction [Cyclophosphamide results in increased expression of TNF protein] Cyclophosphamide affects the expression of TNF protein TNF protein results in decreased susceptibility to Cyclophosphamide TNF protein results in increased susceptibility to Cyclophosphamide |
CTD |
PMID:8634684 |